{
  "directed": true,
  "graph": {
    "annotation_list": {},
    "annotation_pattern": {
      "Species": "^\\d+$"
    },
    "annotation_url": {
      "CellLine": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-line/cell-line-20170511.belanno",
      "CellStructure": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/cell-structure/cell-structure-20170511.belanno",
      "MeSHAnatomy": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-anatomy/mesh-anatomy-20170511.belanno",
      "MeSHDisease": "https://arty.scai.fraunhofer.de/artifactory/bel/annotation/mesh-diseases/mesh-diseases-20170511.belanno"
    },
    "document_metadata": {
      "authors": "Sandra Spalek",
      "contact": "charles.hoyt@scai.fraunhofer.de",
      "copyright": "Copyright Â© 2019 Fraunhofer Institute SCAI, All rights reserved.",
      "description": "",
      "licenses": "CC BY 4.0",
      "name": "The O-GlcNAc modification protects against protein misfolding and aggregation in neurodegenerative disease",
      "version": "1.0.0"
    },
    "namespace_pattern": {
      "PUBCHEM": "^\\d+$"
    },
    "namespace_url": {
      "CHEBI": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/chebi-names.belns",
      "FPLX": "https://raw.githubusercontent.com/sorgerlab/famplex/d9ec0526c20795146a9a6aef17496efe1a36cac6/export/famplex.belns",
      "GO": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/go-names.belns",
      "HBP": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/export/hbp-names.belns",
      "HGNC": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc-names.belns",
      "HGNCGENEFAMILY": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hgnc.genefamily-names.belns",
      "HP": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/hp-names.belns",
      "MESH": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mesh-names.belns",
      "MGI": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/mgi-names.belns",
      "RGD": "https://raw.githubusercontent.com/pharmacome/terminology/efc856fb009a39e4d284269a6801f79ed3d3cf56/external/rgd-names.belns"
    },
    "namespaces_uncached": [],
    "path": "tau/ryan2019.bel",
    "pybel_version": "0.13.3-dev"
  },
  "links": [
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The addition and removal of OGlcNAc onto protein substrates is governed entirely by two ubiquitously expressed enzymes: O-GlcNAc transferase [EC 2.4.1.255] (OGT) and O-GlcNAc hydrolase [EC 3.2.1.169] (OGA) respectively (see Figure 2).",
      "key": "2764cb3c6c7c9d601125b7ec94334f724472b04ed9a712581d4402db9aa8146225324312f3df42b8bc0d18c7447f295074baa3ba4448674a20fdbc4efe3876a0",
      "line": 81,
      "relation": "increases",
      "source": 66,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "OGT-mediated transfer of O-GlcNAc onto proteins is therefore closely tied to cellular glucose concentrations, though notably glucosamine and GlcNAc may also be recycled via salvage pathways",
      "key": "0f73e3d7c6d9d82f3f2ce50f668e27070c7285473729835cf4f2c337d80010a5cc68c197a48759e166b5add4abf53a40294ae509c0f6c6658c573545f828b9c2",
      "line": 87,
      "relation": "increases",
      "source": 66,
      "target": 84
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Knockout studies in mice suggest OGA plays a critical role in brain development",
      "key": "301c201c7d2de3be1696a616a78825c807111e234b3b8af8351838208bc2fa5a5ba58ce2030dea5f9458d44b7092ff24254545b54fc0a2e314f762605e093ebe",
      "line": 107,
      "relation": "association",
      "source": 66,
      "target": 24
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, downregulation of OGT leads to increased tau phosphorylation and onset of AD pathology.",
      "key": "f1c9ff22b60f2fff00a34b172974ee373ad86c80b0492219082bdbe02dc8e889c77b8825f44217da14ef81a32f622fc34ceaf098831f7be09b8191c740190135",
      "line": 343,
      "relation": "decreases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 60
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G was able to decrease effectively aggregation in tau-BiFC cells, even after treatment with BZX2, an OGT inhibitor reported to downregulate O-GlcNAcylation and promote phosphorylation and aggregation",
      "key": "c78120a880e8b94e55c5b43bf19ceb204a81d707875b299203b5b0333891b6245f85080459c6ba76513bb63e18a368dc97687381fabfde4157c92b2f3b5f1be2",
      "line": 408,
      "relation": "decreases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 60
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, downregulation of OGT leads to increased tau phosphorylation and onset of AD pathology.",
      "key": "0f6bf062bd9b174b8c97f0fd282bfb250ea12e1d0c41e82a802741be5fbc976276b761c0bb2a2aadeca6a223bcf96bc3d8c7459a80199737c122efeec38aebbc",
      "line": 344,
      "relation": "negativeCorrelation",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 106
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G was able to decrease effectively aggregation in tau-BiFC cells, even after treatment with BZX2, an OGT inhibitor reported to downregulate O-GlcNAcylation and promote phosphorylation and aggregation",
      "key": "936e26d742db5f878536d39bba0c7aa6260b129056eaf877506f7885f81c82fdf5f01022ff103e1eb2101dbccc2aabcf0b432db58783e9cd6760a9c243da38ff",
      "line": 407,
      "relation": "increases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 57
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G was able to decrease effectively aggregation in tau-BiFC cells, even after treatment with BZX2, an OGT inhibitor reported to downregulate O-GlcNAcylation and promote phosphorylation and aggregation",
      "key": "d39ce60ba2d91dd5ef3904971a12b93930a299559c38da761dfce70ab1c96793870b91c472b06daa622ff0b81d3654a0ebe8d87effb33205f1eb327e1a24cb0e",
      "line": 409,
      "relation": "decreases",
      "source": 66,
      "subject": {
        "modifier": "Activity"
      },
      "target": 11
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "OGT-mediated transfer of O-GlcNAc onto proteins is therefore closely tied to cellular glucose concentrations, though notably glucosamine and GlcNAc may also be recycled via salvage pathways",
      "key": "8b573ff252a3bdecfcc0ec7b329b7efbeec775e2a14c3979162c695810f638f951524e496bf529fa7a8e9db122feeba8a31edd4ec992b0ac5aa3a1d911809d10",
      "line": 88,
      "relation": "association",
      "source": 84,
      "target": 25
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In fact, it has been found that a decreased availability of glucose invokes a considerable reduction in the level of O-GlcNAc present in the mouse brain",
      "key": "3d7a0a557c8d960f8ad73b7269651abc66b44e8355fbc23080943dadda7af9d086ab5027793daa5ff58aee822fe2b1a971ae26e99bc626dbccba786e7b01e568",
      "line": 96,
      "relation": "positiveCorrelation",
      "source": 84,
      "target": 3
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, increased levels of O-GlcNAc via pharmacological OGA inhibition have frequently led to alterations in protein phosphorylation levels",
      "key": "150975a15ef77d00f111ed46549a5af2dc64b6aa07feccc7f54f1730784599579c034a991b4cc0323cb6050e50d8090bd93ed4b9a877da395b1bda0108801e35",
      "line": 126,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 84,
      "target": 65
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, increased levels of O-GlcNAc via pharmacological OGA inhibition have frequently led to alterations in protein phosphorylation levels",
      "key": "933ba7a1ac4a5bcf4882a32e809700557ddb56c56d3c52ff30331b797d9a2002096aed8c8c2ba98bca7ee9df5c8e1a86eeced075155d386f915c7b18a9c1df48",
      "line": 127,
      "relation": "association",
      "source": 84,
      "target": 30
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "A proteomics study conducted by Hart and co-workers found that globally elevated OGlcNAcylation levels lowered phosphorylation at 280 sites while actually increasing it at 148 other sites",
      "key": "69a9867adeaae444bbed3e299c2a3949466f1ff280411d47eccf64130b02561d1bb206f83706374b7fb2195dc869b5b978859a6d4d9d204f8274e8f0080423f0",
      "line": 133,
      "relation": "association",
      "source": 84,
      "target": 30
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gong and co-workers identified that impaired brain glucose metabolism actually leads to neurofibrillary degeneration via downregulation of O-GlcNAcylation.",
      "key": "10eaf490e39534b84351937f5ad30c0ad412bbcd9e4771cb37c5a388c724476ea681d133e036a0261aef3cd0cd8c3fead861e8a18ec6ae4a12f31d69701f17dd",
      "line": 360,
      "relation": "association",
      "source": 84,
      "target": 27
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gong and co-workers identified that impaired brain glucose metabolism actually leads to neurofibrillary degeneration via downregulation of O-GlcNAcylation.",
      "key": "2b13767eb5fe46addeaa033aa75d355d9a317f43c107fdad23c14b8452640513b095b5969647efa880f63692600c246d549138c66737132a84879a9410829106",
      "line": 361,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "negativeCorrelation",
      "source": 84,
      "target": 6
    },
    {
      "key": "8feaccf7109a2e7e475cb9846dc9eac63846269646063fa1aa21ea6f4ac6bd32fb7216df705f957e26bc732bb7ba07a55b96d1df7b24c2f18328f51a4a06d266",
      "relation": "hasVariant",
      "source": 83,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The addition and removal of OGlcNAc onto protein substrates is governed entirely by two ubiquitously expressed enzymes: O-GlcNAc transferase [EC 2.4.1.255] (OGT) and O-GlcNAc hydrolase [EC 3.2.1.169] (OGA) respectively (see Figure 2).",
      "key": "7272772dd767fad7606481e335174d9ad5012d07339507dfe9f311d7d7be7bacd29266d645ad5c2284a71f8aa4135d825bd204ee822290d2f1780377b4b742ca",
      "line": 82,
      "relation": "increases",
      "source": 65,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, increased levels of O-GlcNAc via pharmacological OGA inhibition have frequently led to alterations in protein phosphorylation levels",
      "key": "19dc02393cbc7f4bf7728c4cbf7eb099b382f0eca93981031b0b274cba1dc3a1afc1b32ccd87f8fc210cf6c07684afe7b0f4810f8e9bc06d9beb910f87a3181f",
      "line": 126,
      "relation": "negativeCorrelation",
      "source": 65,
      "subject": {
        "modifier": "Activity"
      },
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "9f6c489c47132a36e4847eb2292e4bb39b5a519a5b6e8219372d4b7ef9966f6e405abd67a0442532c0216a1e5d85569d7828dbd8f40ff1d59bf6a9e11df656d2",
      "line": 275,
      "relation": "decreases",
      "source": 65,
      "subject": {
        "modifier": "Activity"
      },
      "target": 64
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "6ae8f1342fa0548ba52dc75a0cf3a55a52d709a85cf9cd536e49d2a7ee4f7b22aee739ce09b529585dce80eb44fd87c4761b26d916381d6a4f0681d5d2cc86a4",
      "line": 277,
      "relation": "decreases",
      "source": 65,
      "subject": {
        "modifier": "Activity"
      },
      "target": 41
    },
    {
      "annotations": {
        "CellLine": {
          "Neuro-2a cell": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Meanwhile, Vocadlo and co-workers reported that pharmacological inhibition of OGA, in each of neuroblastoma N2a cells, primary rat neurons, and a mouse brain, actually stimulates autophagy via an mTORindependent pathway",
      "key": "9ac71701623a9b73597a45d178d76fdc72cc1deb1a2553960ef3e15e85cd3240633cdd8125d80a9ca4a8c0f40187db69d16780014d4fc52226045a39755f37ad",
      "line": 298,
      "relation": "decreases",
      "source": 65,
      "subject": {
        "modifier": "Activity"
      },
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Inactivation of OGA dramatically promoted HD model toxicity while removal of OGT worked to alleviate toxicity",
      "key": "1e6d9815ee901d4a58071abb4e26cbe1952d10cdc8333de23afec9a19d2b37505f54d09c5328692e294a62d80998e49624ec026103ae87179a330623e4159e45",
      "line": 547,
      "relation": "decreases",
      "source": 65,
      "subject": {
        "modifier": "Activity"
      },
      "target": 55
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "OGT-mediated transfer of O-GlcNAc onto proteins is therefore closely tied to cellular glucose concentrations, though notably glucosamine and GlcNAc may also be recycled via salvage pathways",
      "key": "b5a2fd9115c6f7fd4834acb352485f817d7721d742f33b3e1c67f751be379e84e9f3d5f7c033976bf08517c81a13b011d673f8da216943f99b3a7894f8a01b4a",
      "line": 88,
      "relation": "association",
      "source": 25,
      "target": 84
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In fact, it has been found that a decreased availability of glucose invokes a considerable reduction in the level of O-GlcNAc present in the mouse brain",
      "key": "5e8251bcd625faf96428924b03db95d17a769dc51541588f36988cafd9ab8094cbe260f0bd5bb14ff3e985ead061d8fa924873815f7564874d1d3e9a9676a02e",
      "line": 96,
      "relation": "positiveCorrelation",
      "source": 3,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, hyperglycaemic conditions yield increased levels of O-GlcNAc",
      "key": "5a0bccfe51c84744402968916490afd50c0a50241574c223eef00df4c693e5b016feda3d1f2ebe219c3d515d436188910b2bf1fe9759a195bbc05d0ca38e4295",
      "line": 102,
      "relation": "increases",
      "source": 111,
      "target": 84
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Knockout studies in mice suggest OGA plays a critical role in brain development",
      "key": "12337a26abc09b348e6baccacd2d8ff27a97e25eceba477305fe19382f4428e42229fa156f1984e452494eea69a0c947475d6c5540934171893c82e36681148b",
      "line": 107,
      "relation": "association",
      "source": 24,
      "target": 66
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Though highly potent, PUGNAc (1, Scheme 1) was found to also effectively inhibit human lysosomal hexosaminidase, limiting its utility",
      "key": "3e345a76c434bc5676286c91b3f944c64f4c33a8001e944b4716a55c6054e36f4da569c215a34b9c39db8e5b2e7e4d2fdaaf65ceb44498f05462028f006e58de",
      "line": 114,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 65
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of SH-SY5Y neuroblastoma with PUGNAc, an OGA inhibitor, has increased levels of O-GlcNAc modified APP and secretion of sAPPÎ± while decreasing secretion of AÎ²40",
      "key": "e710e950aa17d7c8cb368ad554f2664bc792d07a4c47dd911885a7af740454afe26d3ece31b5d2a4acf16fa67a46c334186cf23be109203b5c8ce51cb656621a",
      "line": 473,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 65
    },
    {
      "annotations": {
        "CellStructure": {
          "Lysosomes": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Though highly potent, PUGNAc (1, Scheme 1) was found to also effectively inhibit human lysosomal hexosaminidase, limiting its utility",
      "key": "7f0c2097cab964fbbf2f00b6e9713a9f015097fcaa2cf78499cbd22df2e0043081ec41638a0c04ceca29d59522db9ebeca4594f375ec9e40ac65486b2a3f3303",
      "line": 116,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 21,
      "target": 19
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of SH-SY5Y neuroblastoma with PUGNAc, an OGA inhibitor, has increased levels of O-GlcNAc modified APP and secretion of sAPPÎ± while decreasing secretion of AÎ²40",
      "key": "88dc51aacb1faea1c5a67969befdc74ff2ab43f1a4195b00a16aaa363385b245825307587fdac41503bc1aa540494ae9d02f4719f9cadb0c71a8e9cbc2e7692e",
      "line": 474,
      "relation": "increases",
      "source": 21,
      "target": 51
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cell Membrane": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent work indicated that O-GlcNAcylation of APP promotes its plasma membrane localization, facilitating its non-amyloidogenic processing",
      "key": "2d8f9b426e13fd7250a058209f1ac890bd501944119263c9bb9c0c4184453b67e74955b41c76e6a3932441113e803c0677fff48c5dfd5af0a79d6073b4744f50",
      "line": 501,
      "relation": "increases",
      "source": 21,
      "target": 51
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of SH-SY5Y neuroblastoma with PUGNAc, an OGA inhibitor, has increased levels of O-GlcNAc modified APP and secretion of sAPPÎ± while decreasing secretion of AÎ²40",
      "key": "8a5ca12f91891a0454fb32be4b55d854111ec580fdf7f19e3b37e7129eabc3a075148bec4d950bab821fff33f877015bc7d36c0b7cd143358409147c0c6229af",
      "line": 475,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 21,
      "target": 48
    },
    {
      "annotations": {
        "CellLine": {
          "SH-SY5Y": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of SH-SY5Y neuroblastoma with PUGNAc, an OGA inhibitor, has increased levels of O-GlcNAc modified APP and secretion of sAPPÎ± while decreasing secretion of AÎ²40",
      "key": "cce1ee80fa8088b701fb8cc35e54a1a5faec538d7a4fbe69a36937839edefd16a667072a1f87d5c58e9426c05edf1df04ee918dd204b0aab86f509d39f5ae062",
      "line": 476,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "intracellular",
            "namespace": "bel"
          },
          "toLoc": {
            "name": "extracellular space",
            "namespace": "bel"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 21,
      "target": 0
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PUGNAc treatment increased the rate of APP trafficking to the plasma membrane from the trans- Golgi network and decreased the rate of APP endocytosis",
      "key": "0cc665f559741441d113f58071b5b0deb6e5d63134d020e351d8601c7b732d1e9c74da02e8e9a1bd161fe94432afe69f515ec6ea56b95187af3aaeb7b1900551",
      "line": 494,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "trans-Golgi network",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "plasma membrane",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "increases",
      "source": 21,
      "target": 49
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PUGNAc treatment increased the rate of APP trafficking to the plasma membrane from the trans- Golgi network and decreased the rate of APP endocytosis",
      "key": "62f8d30d36e050bd9f677c8c38b2724d578f2efcf0177dbd5a976faf80faaddd5b0eeb1ef9999f11ca819a551bf38de7e6442bbc97a5ae09b3cef97e46f5ef69",
      "line": 495,
      "object": {
        "effect": {
          "fromLoc": {
            "name": "extracellular region",
            "namespace": "GO"
          },
          "toLoc": {
            "name": "intracellular",
            "namespace": "GO"
          }
        },
        "modifier": "Translocation"
      },
      "relation": "decreases",
      "source": 21,
      "target": 49
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cell Membrane": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent work indicated that O-GlcNAcylation of APP promotes its plasma membrane localization, facilitating its non-amyloidogenic processing",
      "key": "15cdac30d6085253785836733a1a601572c945f0d95ebe6263568b07e9f0860c52b0173301ffaea4e0b3a98ff07ed13e1e079c05b36e65f2ef91f0ba8f9a9381",
      "line": 502,
      "relation": "increases",
      "source": 21,
      "target": 34
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G is able to permeate the blood-brain barrier and is highly selective for human OGA",
      "key": "81018cf9f61725947249f6040ff9a974d99b58c18f46cb953bf71398ed7967dd42d7b67ea926e3b6a4717d3ffc256d80e5e256be4e676143a335f06eb342f99b",
      "line": 121,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 20,
      "target": 65
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "9092bafe5a0a79c422a8770e1320c82010ca900cd520c78b678e6dbb8954a679d2c9b824b1a34a0d317727840446d32bdb6257ef9ad2205abc95f51cc205dcce",
      "line": 274,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 20,
      "target": 65
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment increased levels of monomeric ASyn after 7 days by 50% relative to the control.",
      "key": "4ef848b5f05d1d89a4ce93589d1a1de65fadb7bf0e4e9c7cf7aa51d76e65f8b50f1c0a25b89eb5eb4fc9f9bcece3a45af1d69adc09cb56323e61182d5fc2cf90",
      "line": 284,
      "relation": "increases",
      "source": 20,
      "target": 67
    },
    {
      "annotations": {
        "CellLine": {
          "PC-12 cell": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Acute treatment with Thiamet-G effectively decreased phosphorylation of tau at pathologically relevant sites, Thr231 and Ser396, in PC-12 cells",
      "key": "480fca1d2a97c43a0c5218994dca4e555c9914033bc37d04a34ee0bfdd19d0f42b15790db2bd166b4d3948c5e046bbc6c3bd3296d316464dd038c83c110428dd",
      "line": 397,
      "relation": "decreases",
      "source": 20,
      "target": 62
    },
    {
      "annotations": {
        "CellLine": {
          "PC-12 cell": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Acute treatment with Thiamet-G effectively decreased phosphorylation of tau at pathologically relevant sites, Thr231 and Ser396, in PC-12 cells",
      "key": "eae1d9b8b1692de203ffed8adf062c949ba675885a69daf42459ab162649eb8ae698e40c76e492f44f7c79aa61f8ca7bfea83ff6ff03928fcfbc12ccf0a9d6f1",
      "line": 398,
      "relation": "decreases",
      "source": 20,
      "target": 61
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G was able to decrease effectively aggregation in tau-BiFC cells, even after treatment with BZX2, an OGT inhibitor reported to downregulate O-GlcNAcylation and promote phosphorylation and aggregation",
      "key": "ddddd500f2ba6537d87d3162332c54d97ca4203136dba0187f8e08dde10b3d6a47b405bebce685608c27e96b3659c8ccb5d9819f091b9290864b7e236a2e09cf",
      "line": 406,
      "relation": "decreases",
      "source": 20,
      "target": 11
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Long-term treatment of JNPL3 tau tg mice with Thiamet- G increased levels of O-GlcNAc modified tau while decreasing levels of tau aggregates and neuron death",
      "key": "64f2676d69cb933d8b2b055fb11526021aab12f5318128d4e4e0964f1374a627f0548e6dc6e9e6b09bb57e5f8f8df7b795678294636a92d10c972a770011102c",
      "line": 429,
      "relation": "decreases",
      "source": 20,
      "target": 11
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "34e53b1d81d5dddf27f5778954eb2a0b2295b0b6f08f5aa322410cd086c08edeba69bcde08c54b490985fc453d709cc99e44cf64f6b5818a4836a7ef6190116a",
      "line": 447,
      "relation": "decreases",
      "source": 20,
      "target": 11
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent studies on rTg4510 mice found their chronic treatment reduced pathological tau in the brain besides total tau in the CSF also.",
      "key": "793cb3bbd0ed88fc1c5492ed562887846ca51c9573a04683fdf4390916a1bb79f16052672e81c43f19be083bd782f8ad7c7b6e6f8dac0093b11db564b0874fad",
      "line": 456,
      "object": {
        "location": {
          "name": "Brain",
          "namespace": "MESH"
        }
      },
      "relation": "decreases",
      "source": 20,
      "target": 11
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G remains effective in vivo, efficiently reducing phosphorylation at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus.",
      "key": "afde99ce1882915c928c260286ac08d1ed9152a74cff00ab01fb97a80aad897abc5a51712b7dd44adf2d4e9a09dda170235148101e8614aecda8a54927cd9673",
      "line": 417,
      "relation": "decreases",
      "source": 20,
      "target": 103
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G remains effective in vivo, efficiently reducing phosphorylation at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus.",
      "key": "53c9b270db126676fbc901eaf4c4ebb0a81ba207f67226371fd3af28722a2c96aeace93c2bff88d7ec825d46479a0f4d856cef82c0ba904c7d30840caa4a9ccd",
      "line": 418,
      "relation": "decreases",
      "source": 20,
      "target": 101
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true,
          "Hippocampus": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G remains effective in vivo, efficiently reducing phosphorylation at Thr231, Ser396 and Ser422 in both rat cortex and hippocampus.",
      "key": "8a969169c7120bdc4218c5e46e71caa4b3f03360632aa2873fb9c405951443551b72a6b6492331c6694757320ee224e00a83dfed8e5dae60267acfafd0aa91d5",
      "line": 419,
      "relation": "decreases",
      "source": 20,
      "target": 102
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Long-term treatment of JNPL3 tau tg mice with Thiamet- G increased levels of O-GlcNAc modified tau while decreasing levels of tau aggregates and neuron death",
      "key": "57e86c71c38bb2ee77b97fab1c89d003bcd657ca07f978328dd1a655a459c49b52e886d4a31bcc48f1998be4a1c4f934762aecb75a9f379cd3e4668af84d2e67",
      "line": 428,
      "relation": "increases",
      "source": 20,
      "target": 86
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "1951dfc750973a2670882ddb7faf10447fba7dd61197453a0330d216a51af3c40310458f12dd8029e1aa8e0d39145bfd50f7525ba990fd0e3803249164aab4ff",
      "line": 441,
      "relation": "increases",
      "source": 20,
      "target": 86
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Long-term treatment of JNPL3 tau tg mice with Thiamet- G increased levels of O-GlcNAc modified tau while decreasing levels of tau aggregates and neuron death",
      "key": "5df0d804875c35d5108941d68d604a71741bcf4046b3de98c4ca4ecd279e7fee0c9dd1cda7818b12e6a6d6b24c2160edb61f4fc4115d2493f08947f0f61de33f",
      "line": 430,
      "relation": "decreases",
      "source": 20,
      "target": 29
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "938d2c9158a390960926309a48486b2ba5329f5b139b85d5eca48f34f1e1f4ba4c8c09dc096c314fc13358df8f22950b403ac128e64c761f4cd807702527fb98",
      "line": 442,
      "relation": "decreases",
      "source": 20,
      "target": 89
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "70190503ed7825946eeeb662fa4e0df7cd99a30bb96f3f9ec87cce2b2a322bdb56a7314d22971ac40bcf9bea29d605a3b084d16fb5aaa423808633a558f56059",
      "line": 443,
      "relation": "decreases",
      "source": 20,
      "target": 93
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "2f6b023709f463bced173142ed6befe45d2e9e2cda949dbd92330e1bd52fac30f358e4531888217b73910a171a52a58b7a31c214cfd5c4eb3a820a453151cf2a",
      "line": 444,
      "relation": "decreases",
      "source": 20,
      "target": 90
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "3c5a365e338050e4efa39b05d9fa1643ad8a072f249f908b8ba214549ff569a72a376f3b40d6bf389a1b7e96a58271523184a8892602c055dc7250b85591d9c6",
      "line": 445,
      "relation": "decreases",
      "source": 20,
      "target": 91
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In rTg4510 mice, acute treatment led to increased tau O-GlcNAcylation, reduced tau phosphorylation at epitopes S202/S205, S626, S356 and S396 (notably excluding S400), besides reducing levels of pathological tau aggregation",
      "key": "253031f98e7385e74b41aee2433ee786268ec25c75133a8606413cce56e51e545e9d49e021226670fbc6c9de79a7b6ef6fb2a02f4a30493edce5df2e78d5393c",
      "line": 446,
      "relation": "causesNoChange",
      "source": 20,
      "target": 92
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent studies on rTg4510 mice found their chronic treatment reduced pathological tau in the brain besides total tau in the CSF also.",
      "key": "4830c20e85b0c24359e25cdea9b5e8be8746ea425a29445a970179922ec809a4fa5d988eba5fff29ac99e8174a46e40328b6d03e065742cc335c968805c8d82a",
      "line": 457,
      "object": {
        "location": {
          "name": "Cerebrospinal Fluid",
          "namespace": "MESH"
        }
      },
      "relation": "decreases",
      "source": 20,
      "target": 56
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment of tg TAPP (tau/APP) mice blocked cognitive decline paralleling decreased AÎ² and plaque levels while not affecting tau phosphorylation",
      "key": "e06a173bd3f5bda76d844c9084d3796a9ae20aa56874a01e0ec84e83589c578eecd43cddaa1f4134fa3836782f5f5fc8e7a6c6ec533d1639d9d1fade290c87a5",
      "line": 510,
      "relation": "increases",
      "source": 20,
      "target": 33
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment of tg TAPP (tau/APP) mice blocked cognitive decline paralleling decreased AÎ² and plaque levels while not affecting tau phosphorylation",
      "key": "32146a1e3fd2b902f8708fa4470c955f0e7824bcd9484d72cb57d017e6867cb688f09cb690cdbd823d7888e6a4f7a09262b8816d02b2eb9ddf14356fdbab755f",
      "line": 511,
      "relation": "decreases",
      "source": 20,
      "target": 1
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment of tg TAPP (tau/APP) mice blocked cognitive decline paralleling decreased AÎ² and plaque levels while not affecting tau phosphorylation",
      "key": "08bfa24ab11a2c27aa7212cf586d01d03de006ff223961dbdd1833506d1e01e7bb88736472f126c7bbe4a08d2661dd00b78d7fae21e7fef7eb0e31c030c9b146",
      "line": 513,
      "relation": "causesNoChange",
      "source": 20,
      "target": 88
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, increased levels of O-GlcNAc via pharmacological OGA inhibition have frequently led to alterations in protein phosphorylation levels",
      "key": "5fe486afabe922c52f6c382a50586cedc2402c15f501b5eb027426007321dc8c6e3be8337bc43942a12c807b63152635ea743112f1bcb9714ae64bbd05f54324",
      "line": 127,
      "relation": "association",
      "source": 30,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "A proteomics study conducted by Hart and co-workers found that globally elevated OGlcNAcylation levels lowered phosphorylation at 280 sites while actually increasing it at 148 other sites",
      "key": "1de8c0e349e1161f8bd4e65973fbac9e95e976ad37c63c8bac178e64acafa6fee2a45a84f192fa8082b4664d143ac4c47de58b53377381faa7cb52c1c37d5d2d",
      "line": 133,
      "relation": "association",
      "source": 30,
      "target": 84
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Substantia Nigra": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PD is characterised by the progressive degeneration of dopamine-producing neurons in the substantia nigra, resulting in impaired motor function",
      "key": "8141e5eb6ad7f491600602280199eebb6282726c3835bdda6fc880d3721e6d19b22bfd4a20efde3372197e7944ff9e668501a9496d78db911bb6898584afc499",
      "line": 140,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "positiveCorrelation",
      "source": 109,
      "target": 10
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The current consensus is that ASyn self-assembly plays a critical role in PD, whether it be a cause or symptom of the complex pathological cascade.",
      "key": "c690ab8d0f10665fd1102a3ef96697d46375e7a46956057a271e27ea63c8d672a72809ae742c6edcb85980346b538b02d30c9af413f084a1f39f9e3a95f650a0",
      "line": 159,
      "relation": "association",
      "source": 109,
      "target": 38
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Calpain activity correlates with disease progression in PD mouse models",
      "key": "100bdb8c64d16a2c4753cf0195c9cfe31b498c843e4934ce2071bfc2c40f7d257527f3a2d4a26e254dcbd8f59978b553d956d3d42b9a13bb66009fb55759b121",
      "line": 201,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 109,
      "target": 82
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "As mentioned previously, calpain activity correlates well with disease progression in PD mouse models, catalysing the truncation of ASyn into aggregation-prone species",
      "key": "2386d21080f93c7c0ae8ab113bd7863ad688703f5b6df98875095513a1f04663a941ec9503251cb01327e461afb63ab786d43c3d03d9e8b87e035d0b9ccc2cd7",
      "line": 250,
      "object": {
        "modifier": "Activity"
      },
      "relation": "association",
      "source": 109,
      "target": 82
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Substantia Nigra": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PD is characterised by the progressive degeneration of dopamine-producing neurons in the substantia nigra, resulting in impaired motor function",
      "key": "9619e26ac42d72c82e721eae3a0c662223e1bcac5dd24a3f7ea2053aa2de70d353869a516858f24fd5ac8dca2386c1a63c9c29b6bb72ed0250b291f619232560",
      "line": 140,
      "relation": "positiveCorrelation",
      "source": 10,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 109
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Substantia Nigra": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PD is characterised by the progressive degeneration of dopamine-producing neurons in the substantia nigra, resulting in impaired motor function",
      "key": "d2e1932895fc5afdf98b9803b17bb197a1db87ebb3f05f4f9e4227dd10dcc308a7971ca5f1b2bc5953cfa9211cff80772577f58d0fd0d6b67daa8bb2bb73a543",
      "line": 141,
      "relation": "negativeCorrelation",
      "source": 10,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 28
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Substantia Nigra": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "PD is characterised by the progressive degeneration of dopamine-producing neurons in the substantia nigra, resulting in impaired motor function",
      "key": "60fd195403626cde6dfbc8a6b083b73d89cc26f3658e5bd6289558aabd79c16e8499eafe17f7a1d13fe3248577bb94a9134d8e8f552da0ec951e969edbd9d039",
      "line": 141,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "negativeCorrelation",
      "source": 28,
      "target": 10
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "This impairment manifests compromised postural reflexes, muscular rigidity and bradykinesia in patients.",
      "key": "4c09077f353b8e713490bfc41b0c20114b6b1cbe65339549642141edc64de2a52e1a17aeaca864fa9392fa34f106d2b825e9e8999f6a761dd61adbd79430ae1c",
      "line": 147,
      "relation": "decreases",
      "source": 28,
      "target": 112
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "This impairment manifests compromised postural reflexes, muscular rigidity and bradykinesia in patients.",
      "key": "0dde41f712d9bbec967e26392d7fd7132292773a9a31dc552cc6d00b46963d2d5d97911a7573fc769b0c6e8d98fa38b488449637bb4ff3f137fe7185ef91285a",
      "line": 148,
      "relation": "decreases",
      "source": 28,
      "target": 108
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "This impairment manifests compromised postural reflexes, muscular rigidity and bradykinesia in patients.",
      "key": "6cc08c773fd7877daafcdf6e87e12efa30207ed82f37e1e4f58bd1f8714710c7305802072f1aaae4be4c8dfb5f79e4f744504c95e53b7b8e468d065d61a61b32",
      "line": 149,
      "relation": "decreases",
      "source": 28,
      "target": 105
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Point mutations in the ASyn gene (SNCA) underlie familial disorders with parkinsonian characteristics, suggesting a pathogenic role for ASyn accumulation",
      "key": "9d50359b5214a73c9d64761d43cb21fa0526e76f297d29adea4e3e6e2472f5e2de6c7f50b6a61f9fdb2114520bd59cadb32aa6bc682a899af162e0b86ff140a9",
      "line": 154,
      "relation": "increases",
      "source": 78,
      "target": 109
    },
    {
      "key": "892d371737b8a859289caced4c4d763309650497f2e73b58bc379b64d1f7a3a19962c0ee817a361a6bbbcfb96d11c59e50167d5baa9b2fe04a181b6576d47322",
      "relation": "hasVariant",
      "source": 67,
      "target": 78
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Reports suggest ASyn has a role in regulating supply and management of synaptic vesicles,57 while also possibly regulating neuronal release of dopamine, a neurotransmitter involved in controlling voluntary and involuntary movement",
      "key": "b112b1ea1c98fb93f150f79bdbb80cbe9be5a86bb2a7ee50074cd92a45379114b3ed415da438df807f89cf389d98d4b4ac595c1f0961e4590ca218b2fcb1ae84",
      "line": 166,
      "relation": "regulates",
      "source": 67,
      "target": 7
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Reports suggest ASyn has a role in regulating supply and management of synaptic vesicles,57 while also possibly regulating neuronal release of dopamine, a neurotransmitter involved in controlling voluntary and involuntary movement",
      "key": "dad6e754e6ef3975ef8a3447fd349b2d832e0adce5029b54dce06979126e6ce9278bd0a85c31e9f150c75a65245ce89d2d99c9ea8f7cb767e35bad05fbec6c4c",
      "line": 168,
      "relation": "association",
      "source": 67,
      "target": 26
    },
    {
      "key": "9b9d016882948650eb2883dbad8a693caa9e70a871f23d733e1a0d8308e030a311dcbae352c6b6c01e7b21aa4616ad5f5b70dfe2a9aaeee39c88262c633fb385",
      "relation": "hasVariant",
      "source": 67,
      "target": 70
    },
    {
      "key": "8b33ffc00ae7c4456651a2f54c7d222899d0cce3ef452d990817774cf5ea992aa398bc0bf62f1ad8ae6704ff66ffc417aefeb74486233db9a2782aac366b9334",
      "relation": "hasVariant",
      "source": 67,
      "target": 69
    },
    {
      "key": "b138947b9495e4f055174d727a802ae3312df33fbff489895723ccaa760f81a08c22b1b0110928ffcde7882cea96e2aa5178ae48b8c9fae98bbb19e9825393d5",
      "relation": "hasVariant",
      "source": 67,
      "target": 77
    },
    {
      "key": "721f9ab58a7214ed78ace1ddb22c0d2e318d836a343831a2afcda5ac0486f33f067b4e2b20f63b343b4ea179e138c6ec6a2104eb31521907fb45280309f6562a",
      "relation": "hasVariant",
      "source": 67,
      "target": 71
    },
    {
      "key": "11df7f22a06b4fa95285407b5cc5bac4482912a7ce5b8eab3af134968c1358584c8df61d49961196a8b91ab8d5c8a99cd99ac83fd988019e8ffae7e91642beac",
      "relation": "hasVariant",
      "source": 67,
      "target": 74
    },
    {
      "key": "7d2141f39067ad9397bd0ab1628d0253d780930d04c1267533d3faeeaf1dd73186fdcffb3e801d9979c13dde98c128595cc571570c2efd4a16023969e2316381",
      "relation": "hasVariant",
      "source": 67,
      "target": 72
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "TEM found semisynthetic ASyngS87 forms shorter fibrils than the wildtype, while ASyngT72 formed only small, broken fibrils",
      "key": "623e60adbbb42b9d22be666d370a160ad8455fe1d8504af4ccb3a4a503c0b3b93f81a21e06e68ea020a6f283691a47c1d63b5cc33f53b5d5cbd621cd480e9b14",
      "line": 231,
      "relation": "increases",
      "source": 67,
      "target": 15
    },
    {
      "key": "71588ad8600f17f669729eb4c4c38f2af02f180345f0a32745632098327e46d1a132c6f27fd0f2d38a3b180e2fcea7662f816d6661ba3d6088f349685ff726fe",
      "relation": "hasVariant",
      "source": 67,
      "target": 75
    },
    {
      "key": "2b1a18ed8fd7f2db3d2e2139ed1fee9f44470491b81264d70145c63c991ebe1453f0d4c4584a9b8f5bab0680600d15646cf56db05d8f21ee94792c85703726fa",
      "relation": "hasVariant",
      "source": 67,
      "target": 76
    },
    {
      "key": "77aeb28bf0e102de5693d9f871745a6d4f500afe9e49fd29a9e4eff51fea213999a872f04c38f583c52e0a6983a83863cba9fda63eb51511473a2c2457ab91c4",
      "relation": "hasVariant",
      "source": 67,
      "target": 73
    },
    {
      "key": "22661154caef74f527310973d855a3dff1745e1b9aa181e6c4d0cd876b2e7281b61279004c09a5eff25efe1457eea06a78116bd9c98a89293bf666891a1727cf",
      "relation": "hasVariant",
      "source": 67,
      "target": 68
    },
    {
      "key": "d70240cbd86587b1d77e94b4af342845f9e1fb3efebdc94809a915c371fd82106b44dbc9f7941c5b843b20c09d9ea81a0330a6c4cde0d2a991ad2fc2c2fcb08c",
      "relation": "hasComponent",
      "source": 38,
      "target": 67
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The current consensus is that ASyn self-assembly plays a critical role in PD, whether it be a cause or symptom of the complex pathological cascade.",
      "key": "9a76d2828532ccbd71e5eca94257c321933b3f7e1fddbe3f915fb401a4e8d41a4d06e1f4a4ed65732012db6011c623dcee30a48011797503d6adea308a60c84f",
      "line": 159,
      "relation": "association",
      "source": 38,
      "target": 109
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Reports suggest ASyn has a role in regulating supply and management of synaptic vesicles,57 while also possibly regulating neuronal release of dopamine, a neurotransmitter involved in controlling voluntary and involuntary movement",
      "key": "791c40a501599d6428b90257789830eb1f5a3fb1d3d18170a39dfa31dc280a848c0ee87772be162ec33acf4ea4cfd7ae43385c7899cac255e677a790ce9822d0",
      "line": 168,
      "relation": "association",
      "source": 26,
      "target": 67
    },
    {
      "key": "fdfc6389408dcbded58ce55eed572a6c9de5deb4ccb954dcda938b1ee0239f05e128859c33b65f028085d421d701087f505dccd0ac2014604992c26e4545d2db",
      "relation": "hasComponent",
      "source": 35,
      "target": 4
    },
    {
      "key": "ed83008f91b00270d380e00e1d685ddddcdd3109c830cacabe2a8d414e8fe5b0bd522ce64efedea8c13baa3fa2a2a0001427a529a4ab2db2f357fb7db2dfee62",
      "relation": "hasComponent",
      "source": 35,
      "target": 67
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cell Membrane": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "ASyn binds simultaneously to plasma membrane phospholipids (via its N-terminal domain) and to synaptobrevin-2 (via its Cterminal domain) to promote SNARE-complex assembly.",
      "key": "cf89852acbe4c26c5ff5032be994cf6207e6110e1b439fcfdb6247920666c8200d1a8959ea646293fdb9839dc50f5ec5f89099ba0f12b57995cf310e109b6629",
      "line": 174,
      "relation": "increases",
      "source": 35,
      "target": 22
    },
    {
      "key": "c4cd67590c9334a284cad56c0b1c2b1d038077ca87d117370b474e3fb9845b0c7da668381b3b40c1296be17a46bb2b698cc1601b77fa6c3f0f0fa28b559a06e9",
      "relation": "hasComponent",
      "source": 39,
      "target": 67
    },
    {
      "key": "2c6a04c9b9dc2b8658eec0e223000885dc7df76214a4245968704db5a5e831bdbae0001cc2f71201257ffc9bfb5abf3f230ce899b674bdac0d6bba9bc37e32f2",
      "relation": "hasComponent",
      "source": 39,
      "target": 81
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "ASyn binds simultaneously to plasma membrane phospholipids (via its N-terminal domain) and to synaptobrevin-2 (via its Cterminal domain) to promote SNARE-complex assembly.",
      "key": "0a85ffb7677004c48aa2b698ecce6f23206c26bc121210c850525b156bce8a65feb6ef091ef08ae73c2ddf74769ff57fca093c7dc00603e4ce7516818b0bdf41",
      "line": 176,
      "relation": "increases",
      "source": 39,
      "target": 22
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "It has been suggested that large ASyn aggregates actually work to sequester other harmful conformers, thus acting in a neuroprotective manner.",
      "key": "6cadf0f6d685532347d48811b11e86204e33a230cd206ca279af047615fa59833e294d34f38a00b3f27847b9d5b1fb679ad9eaf4a387ad69a48be8a8151883a5",
      "line": 180,
      "relation": "decreases",
      "source": 14,
      "target": 29
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The authors suggested that OGlcNAcylation as studied in their case, had promoted oligomer-formation underlying the reduced aggregation",
      "key": "59399b4fa2ebc82f14d538e752dcc8a94328cc8f6030dd4bd1adbd7aa776343f97a7e4fc986c79c317538cee3a30b6252f938386877a7cc8b1c0ba633f4cd973",
      "line": 268,
      "relation": "negativeCorrelation",
      "source": 14,
      "target": 16
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Notably, cleavages at the ASyn C-terminus typically increase the resultant truncated proteinâs aggregation, as has been demonstrated in vitro and in overexpression experiments",
      "key": "6ffd25333351119455bb69f55f071fe9536685b9c75150166044488d4b198d10cef06baa2eac92467178a2eaa22cac3e091697f4e2bd885b6b9f51ab2783fcfe",
      "line": 186,
      "relation": "increases",
      "source": 70,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Specifically calpain, a cysteine protease, cleaves soluble ASyn at a number of sites.",
      "key": "9a51906f6c838413e203aebcee0639dc9ece6ee298bee2fa51175b55185c58621b58eb6c5d55263f5d024faf4a52a1e5f431c406f646d2fdd0f4a03e9332fbaf",
      "line": 191,
      "relation": "increases",
      "source": 82,
      "target": 69
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "As mentioned previously, calpain activity correlates well with disease progression in PD mouse models, catalysing the truncation of ASyn into aggregation-prone species",
      "key": "b3e29f89202bb106a522768af71f0f39ab5e811bcbdd4d4f77484e46afcd33dc4fd809798ca0704df03a1af87386b2d6a84f93b1a612f304872a59b3e56300ff",
      "line": 251,
      "relation": "increases",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 69
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Calpain also cleaves ASyn fibres to generate C-truncated forms which promote seeded aggregation",
      "key": "d07f93d8429cc6f6cadc6931d30070da724d5ba214871c4f417d691d0c2324a312c642cae7fd59f5b456d23b61cc4b39c863874017bc861b9cf018ebae24ce70",
      "line": 195,
      "relation": "increases",
      "source": 82,
      "target": 47
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Calpain activity correlates with disease progression in PD mouse models",
      "key": "1b20473f2742aef6e6422ced86b38ef63e593f425cb3efb906cf9b2d2442015985e541144aaf8b740f59863ea6ec2a25924e17c58799162286ea3278b3962f61",
      "line": 201,
      "relation": "association",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 109
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "As mentioned previously, calpain activity correlates well with disease progression in PD mouse models, catalysing the truncation of ASyn into aggregation-prone species",
      "key": "690651bca9db7a856a25cd9ca92c8329896aed23c8117aebf801f3b774c85dfba6fd04cd663c48def01fa939fd0c4f4f01b3a0ba93a3f1d35287ca7cb2c15927",
      "line": 250,
      "relation": "association",
      "source": 82,
      "subject": {
        "modifier": "Activity"
      },
      "target": 109
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Both the synthetic ASyngT72 and ASyngS87 peptides exhibit strong resistances to cleavage from recombinant calpain, where unmodified ASyn is degraded rapidly",
      "key": "eef6b94ac8ff21cd39f25f419e45fdc5c744027154299fdc79d3943cc58acf785df75c3207040d7c5f0be65d2743f41daa28458601520e73050fd496fcfea19f",
      "line": 259,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "causesNoChange",
      "source": 82,
      "target": 74
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Both the synthetic ASyngT72 and ASyngS87 peptides exhibit strong resistances to cleavage from recombinant calpain, where unmodified ASyn is degraded rapidly",
      "key": "402c2f95bf785a70795a4ffee56ca37e2cfdd8f72068bf5a69baef608278fe44393db95a2a2cfb577724296f9cb0f7367f3b3ccc7ebd6a54110248f755a9bf15",
      "line": 260,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "causesNoChange",
      "source": 82,
      "target": 72
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Both the synthetic ASyngT72 and ASyngS87 peptides exhibit strong resistances to cleavage from recombinant calpain, where unmodified ASyn is degraded rapidly",
      "key": "2c6efa50a9e6d2689ee23b68d675b2e6607711a116b245d577c4f813ea4e918556e61ca4a78427f76ddeeaddb9d175bf73409a870d51e6233649797bbce140f2",
      "line": 261,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "increases",
      "source": 82,
      "target": 67
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "As mentioned previously, calpain activity correlates well with disease progression in PD mouse models, catalysing the truncation of ASyn into aggregation-prone species",
      "key": "ba9334ff234e4a82f0b76893ac235ee850f753a126b09f86482855935a66905ed5462b6f372a75f63501a04e18047ae1e203a8a9a70ea83b46d544290d385c2a",
      "line": 252,
      "relation": "increases",
      "source": 69,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Calpain also cleaves ASyn fibres to generate C-truncated forms which promote seeded aggregation",
      "key": "cec6efafefe1dfa2f1dcefa153ddd3b83ca7bfb69fb5393dfd21a8f90c7e871191c149e2cff8935a537144f0530f4c96bfeb7d0ab6bb89045bbdec47db84551b",
      "line": 196,
      "relation": "increases",
      "source": 47,
      "target": 14
    },
    {
      "key": "e77717586b2c9a5089b643e0c781a703020ce4b43353b69a5ef5efe51819dfe0558a95eff382207e70990638cb836128498b2509f71b0d4219e63737e6e108ad",
      "relation": "hasVariant",
      "source": 46,
      "target": 47
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "An estimated 90% of the proteins constituting ASyn aggregates bear phosphate groups at Ser129, suggesting that ASyn phosphorylation, or at least elevated levels of phosphorylated ASyn, contributes to PD pathogenesis",
      "key": "1f7690505647d9fea3aa0b61bbaf8b01a2be9034910a5aac8bd360fe3dfd50776dedaabca0a4c30b55ef0592c5c578e6107691cf66e1c3eb28d59fa73e9818eb",
      "line": 209,
      "relation": "increases",
      "source": 77,
      "target": 109
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The O-GlcNAc modification has been shown to slow the aggregation rate of ASyn relative to the wild-type.",
      "key": "2b42467a7faae0da0ab017c02320440fb4eb67f37caaffafa182943f9da391266814cbae2dd52f97fb820c994b70fce9035ca139060b51c4e611643d243b77c8",
      "line": 214,
      "relation": "decreases",
      "source": 71,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The authors suggested that OGlcNAcylation as studied in their case, had promoted oligomer-formation underlying the reduced aggregation",
      "key": "f54f3703677ed4275684a8ddd7a801d9c18354a803aa3476bef9a9838bbb7e2831f572cd6e1bdc72c84b72bd647553e99fce6373869243dead94624e8128abad",
      "line": 267,
      "relation": "increases",
      "source": 71,
      "target": 16
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Initially it was found that semisynthetic ASyn bearing an O-GlcNAc unit at Thr72 (ASyngT72) displayed a reduced self-assembling propensity relative to the wild-type during thioflavin T (ThT) fluorescence assay",
      "key": "f3ec469b0a85355894ca70b56dd850512bedd7aac47e0e7f68b03865dfbe53350d2150b77bc6accec5c6b7b617489d2e95b26c2925ff931588865d439b3d3b51",
      "line": 221,
      "relation": "decreases",
      "source": 74,
      "target": 38
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "In fact, ASyngT72 did not form aggregates even after 7 days of incubation",
      "key": "75c11293bbf2ee96a57a101556f284a5fb9fee99f734709b630e8ce2dc80798a1de4e6bd67e77e0c9229a92d70df71c9c29d732083f9d2b600c373a7ad5e74d3",
      "line": 225,
      "relation": "decreases",
      "source": 74,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "TEM found semisynthetic ASyngS87 forms shorter fibrils than the wildtype, while ASyngT72 formed only small, broken fibrils",
      "key": "2d760e7bf47a596f8c96c8070e8344356b7fc0a12a8d58233856bdccf49e5d0b951ec0d162dc887338783944be348ecd030656fd307592ac6938e9ea0159dced",
      "line": 230,
      "relation": "increases",
      "source": 74,
      "target": 15
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "TEM found semisynthetic ASyngS87 forms shorter fibrils than the wildtype, while ASyngT72 formed only small, broken fibrils",
      "key": "7f0a06332649dc31e22ad6978026a4aab6bdafcdb7589000a4fe57f930634b1e7778fbb1bc72e86e076f5ee96852cd2119dee5aeb602917daf37ee48e8a4ae2f",
      "line": 229,
      "relation": "increases",
      "source": 72,
      "target": 15
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "ASyngT75 and ASyngT81 formed rare, highly irregular aggregates, and the peptide tri-O-GlcNAcylated at all of Th72/Thr81/Ser87 did not aggregate at all.",
      "key": "21c4b523bceab69d39174b9c51305c2e925f98b341f55e5f85a37cd30dcd6cc841a597a347ff5399d71fa962711554e25ba67c0de62d3dbbbcf269b2bf0fa7c7",
      "line": 236,
      "relation": "increases",
      "source": 75,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "ASyngT75 and ASyngT81 formed rare, highly irregular aggregates, and the peptide tri-O-GlcNAcylated at all of Th72/Thr81/Ser87 did not aggregate at all.",
      "key": "2376df8c1ec355403c99a1185d5742d975a854c10992c28409889380314aa7b287b9d9e31c6c5c87418bc92f306862f99902798703aba67114a40352134ad10a",
      "line": 237,
      "relation": "increases",
      "source": 76,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "ASyngT75 and ASyngT81 formed rare, highly irregular aggregates, and the peptide tri-O-GlcNAcylated at all of Th72/Thr81/Ser87 did not aggregate at all.",
      "key": "4221cbdc5ce31e55adc3c754d7e789a2106da6bde2731904ceb1e529e937faa436ce576cf1e86eaa2df80abb54fc2f38cc8adf1ec1f9d574cd865059937eb988",
      "line": 238,
      "relation": "causesNoChange",
      "source": 73,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "An unmodified control, ASyn68-77, significantly accelerated wild-type aggregation while the GlcNAcylated analogue did not.",
      "key": "e5433702f9bbc8186868ab34c01e3d61727e5d6031e15fdb7be075fbdaa13dbffa76b2b12bdaa5f7065c68d70364815f960b8413fb7b94f4a6821a131d676c69",
      "line": 243,
      "relation": "increases",
      "source": 68,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "The authors suggested that OGlcNAcylation as studied in their case, had promoted oligomer-formation underlying the reduced aggregation",
      "key": "2962577e2850c78eba6fb3f8baab4df9b6eea52aa8cbacf7c2eea844839031b3e088454a77eef47d13291a5bac5e06de4d07c25731693d49033ac7c915d08f7b",
      "line": 268,
      "relation": "negativeCorrelation",
      "source": 16,
      "target": 14
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "13695b3a784a2c2a6f945d980357727bd07195332a699ae9416f4d88f560d1b18d0d8902f4f142da640106ab1869695675b1d25edf40da92e5d1b564b220353d",
      "line": 276,
      "relation": "decreases",
      "source": 64,
      "target": 32
    },
    {
      "key": "309c35f98f4ace7db5eb001053c2117eb1cd88b15143c70c638af33466fef1e8e76155fd83e16262185580e0e21fa9730c839587f5d32cd1b3319ffd97cd6512",
      "relation": "hasVariant",
      "source": 63,
      "target": 64
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent re-activation of autophagy via rapamycin, an mTOR inhibitor, attenuated the increase in ASyn accumulation also.",
      "key": "aca9ece107cca35824e4575c3036075ec8dbf6b770aa284d1ec396161a9f52d4cdf1285a2794a6299f64e5248c81d864c9307451828519579aad1e7013d18179",
      "line": 290,
      "relation": "decreases",
      "source": 63,
      "subject": {
        "modifier": "Activity"
      },
      "target": 67
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "ac897ae061658c6cb9865ae1e1e9ccea4cefb2c5b4592ebf071eecca9ff2430b68e443e64dddf9434a127b597823867114130a685bf68975a386f3c0d9b1d77c",
      "line": 279,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 32,
      "target": 67
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent re-activation of autophagy via rapamycin, an mTOR inhibitor, attenuated the increase in ASyn accumulation also.",
      "key": "7e8021c63e012a762c2607030c189a7e4a818d2573855bc43ce0dfc0f9ee54c6f7216894aa40c31482ac0872847970320beea381e57f83c2234bab2cb8d9850b",
      "line": 291,
      "relation": "increases",
      "source": 32,
      "target": 67
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Zhang and co-workers found that OGA inhibition via acute Thiamet-G treatment promoted phosphorylation of mTOR and AKT, leading to decreased autophagic flux and subsequent accretion of dysfunctional ASyn",
      "key": "6a4e3028533ac8fe66388d921d1630b6977a472fc0fcab35734134d9cbc0bfb577776d2ef10baa0c2c379bc0df1318513c20ea884d40db827501a23780fecbdb",
      "line": 278,
      "relation": "decreases",
      "source": 41,
      "target": 32
    },
    {
      "key": "e116efc1e42b1489df61c436ffaafcd0372249b6e2dd4b3fe8b8586cae5efcc671048f5065d7e0a9164d380e4e7e449feee77aef4181eeb18af8d249b730ced3",
      "relation": "hasVariant",
      "source": 40,
      "target": 41
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Subsequent re-activation of autophagy via rapamycin, an mTOR inhibitor, attenuated the increase in ASyn accumulation also.",
      "key": "e68936ac82732d68e5d62e79af0c2a4b84bfbd83fcb5a7491d0d562df7134b1a4350f612845b41e0a3d4ce1373cac343f70e1c03295e5824c4e43ee51c739f25",
      "line": 289,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 5,
      "target": 63
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Meanwhile, Vocadlo and co-workers reported that pharmacological inhibition of OGA, in each of neuroblastoma N2a cells, primary rat neurons, and a mouse brain, actually stimulates autophagy via an mTORindependent pathway",
      "key": "569d31f1496d9fa2f784fe38be8b91bd1c83e14ced7d8561e25176910912c4bbbe37e5c3b474a37b6cb5a9ea4fccd92c23f5796b894fde17bb5c4619a0db6d30",
      "line": 302,
      "relation": "decreases",
      "source": 94,
      "subject": {
        "modifier": "Activity"
      },
      "target": 32
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Neurons": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Meanwhile, Vocadlo and co-workers reported that pharmacological inhibition of OGA, in each of neuroblastoma N2a cells, primary rat neurons, and a mouse brain, actually stimulates autophagy via an mTORindependent pathway",
      "key": "d92017051511307653422f4bfa653b2bd726205bac54678cdc3b62fd9776209cf785dd2a27dff61cd5db69bb01ff203d452f313d7f3881fafbb3dbe3eb267d4c",
      "line": 307,
      "relation": "decreases",
      "source": 104,
      "subject": {
        "modifier": "Activity"
      },
      "target": 32
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Phosphorylation of tau regulates its modulatory functions by impairing its ability to bind microtubules.",
      "key": "6d73e9a4744bce939be943641855e69e3e77c019db5e6941232dcf55d4b56bf603e629137c0e725f6846f6eaab19ef08831386c99266f00fe9ccf450361b6386",
      "line": 314,
      "relation": "decreases",
      "source": 60,
      "target": 36
    },
    {
      "key": "c4e71f1866eab20795e7e1d4b54fe09effb8b376e41712f8a130fe5192e07d83b0749cc2e2297b62cbea4bb7b1033909ea6d6423fa06166cb07543cee4249d48",
      "relation": "hasVariant",
      "source": 56,
      "target": 60
    },
    {
      "key": "9fbd9218812f1cd82827e2d73f3b6af04acbe1f408aaedcdc53c6fc17a36272c67cdcc254874f5473ba4443fa19971fe4877420e735c04f4f7353480d8e1f8b2",
      "relation": "hasVariant",
      "source": 56,
      "target": 59
    },
    {
      "key": "7a5416e59612c374a3a5c6700211dc1b53ebdcab558fbbf695ee4c468852d9e896b3460f9b5fd9218e13e47c11b609233c4bd1f15244ef740563a3a2768efe25",
      "relation": "hasVariant",
      "source": 56,
      "target": 57
    },
    {
      "key": "7f8ad94998747bbb8479859b2470f86281363b83c57fb326115bc2904d3f02dcdf270c5a843601e788933c92638d61192d8dc43d4312722e7e74411c661536a4",
      "relation": "hasVariant",
      "source": 56,
      "target": 58
    },
    {
      "key": "43f3a05a562aea7d640aaac845125159fcfbdd06303b001b5cf1eec04af58dabda000353c3cf4551bae1aea91c8b1be6e3f2669e44287e4a25d0655b1d33aab4",
      "relation": "hasVariant",
      "source": 56,
      "target": 62
    },
    {
      "key": "09505215df0db1264915198df6f54ea647eb376b6ede05f22846b2d289a2907fa049769b8eb45a919e706a2eb7c7a96704537753eeb5e7c30a012888cd5296de",
      "relation": "hasVariant",
      "source": 56,
      "target": 61
    },
    {
      "key": "e30a63cb8051908bbf600613a93906b15c4705e7f7abe5a0ad62a2698f3a5262b6abcc9e9e0cf196429bd9a44486e8fc09c678ea23c20264267b728a4b6bb242",
      "relation": "hasComponent",
      "source": 36,
      "target": 9
    },
    {
      "key": "634e58096a5532932706dd2067ec8bba3b4f9fe5e640db2c3acaccb3b0e9efdaefea7e274911a0cf58de18a8e4b1fdc7e767f1b94021cfbd7dc9940098efdf19",
      "relation": "hasComponent",
      "source": 36,
      "target": 56
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Abnormal hyperphosphorylation of tau (P-tau) results in its detachment from microtubules, suppressing its activity and secondarily promoting its self-assembly into oligomers, ultimately giving rise to the NFTs present in the AD brain.",
      "key": "f7a9fe3a3f31113c2b4467aa5c420b8becfa91c97b41215921941e067adac8b1788f9471e74334ff42e16402adcdc568befe721340c1a0d1cfe65dfc122336b4",
      "line": 324,
      "object": {
        "modifier": "Activity"
      },
      "relation": "increases",
      "source": 36,
      "target": 56
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Abnormal hyperphosphorylation of tau (P-tau) results in its detachment from microtubules, suppressing its activity and secondarily promoting its self-assembly into oligomers, ultimately giving rise to the NFTs present in the AD brain.",
      "key": "f449b0a8778dfc65e02f4a9239d565bb08b5753934bfb80182c9b40306df6abfa71722b1010fc05b27f98d0c3e378943cc3b925136ba10cd131e23d29dcef7e0",
      "line": 323,
      "relation": "decreases",
      "source": 59,
      "target": 36
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Abnormal hyperphosphorylation of tau (P-tau) results in its detachment from microtubules, suppressing its activity and secondarily promoting its self-assembly into oligomers, ultimately giving rise to the NFTs present in the AD brain.",
      "key": "d1a270f4ee26881c4ee490bd7e12ea855723bbb8074355df40079b2c6dc93e122a974fa82f8da0809b5c5ece53afc7c0ccfb6f3f0c6d31097b1123df43a6b9b1",
      "line": 325,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 59,
      "target": 56
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Abnormal hyperphosphorylation of tau (P-tau) results in its detachment from microtubules, suppressing its activity and secondarily promoting its self-assembly into oligomers, ultimately giving rise to the NFTs present in the AD brain.",
      "key": "07031705ad56d61eca735491ed6700fcf2eaf0e428f76fd6d9c9339e0ff29a2da32d8f39b09ae456227ad64d701ff4f642f828039e6a319acea75e5f8738d62b",
      "line": 326,
      "relation": "increases",
      "source": 59,
      "target": 13
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "MeSHDisease": {
          "Alzheimer Disease": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Abnormal hyperphosphorylation of tau (P-tau) results in its detachment from microtubules, suppressing its activity and secondarily promoting its self-assembly into oligomers, ultimately giving rise to the NFTs present in the AD brain.",
      "key": "925d4675f0f7b8af5c7928145cc91f02853e5177f7e2df89a9416f8a455cd88f6414fd912a47c0416112b9abf17282a7926f11071cda6f561e32395ec401f3ad",
      "line": 327,
      "relation": "increases",
      "source": 13,
      "target": 6
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gong and co-workers identified that impaired brain glucose metabolism actually leads to neurofibrillary degeneration via downregulation of O-GlcNAcylation.",
      "key": "93595df787181b380342f6b14150f97026fd7fb6111dbedabe04c2e761dc4f0e81ab15cf430acac0ed8a951ff9884a210ac70f2461c541e715249faf87fdddff",
      "line": 361,
      "relation": "negativeCorrelation",
      "source": 6,
      "subject": {
        "modifier": "Degradation"
      },
      "target": 84
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "It was later found that tau phosphorylation was inversely regulated by OGlcNAc addition in vitro, in tissue culture cells, and ex vivo in rat brain slices (Figure 4)",
      "key": "12a3a198d773d67732b48ce067a63d1e2cbe8dc0489304e9eadca73a295a2d284360f84f796faba372038c8c0dfc069621c10c2f4a712fb06e9a46bc191ed62a",
      "line": 337,
      "relation": "negativeCorrelation",
      "source": 99,
      "target": 100
    },
    {
      "key": "a5c10c0aa149328e108c84d920ed338b4f0717d5d1c0d43f3e76cdfb5d8f0abe33730e422b83a9c052b6e8f084c6b5f7c67fb1e78c4d0887c14d99332d4566fe",
      "relation": "hasVariant",
      "source": 98,
      "target": 99
    },
    {
      "key": "13dfd5e324e943b5b15969ee80cc94c2ee476ba98038149d2d3eea748cda06d59bc0296a07e95ac18a414ec8c83ff561354f04122550f1c3479a8907fea110a6",
      "relation": "hasVariant",
      "source": 98,
      "target": 100
    },
    {
      "key": "927676b9e87641b9e11f4087091b9253de770bc8336f4500eca8aacf50f248e1e8fe9ac7a4f09c0137d90614b8ae094b8be8fa626349ce8458e5d62ebcca62e0",
      "relation": "hasVariant",
      "source": 98,
      "target": 103
    },
    {
      "key": "2bba626db0242764c369450eec2de6d4628da74a9860db79f00d246975cd3b6c1a46422f649c3cac311a820a5200a9f45503e3e4a9c9f06ecc39e94ac01b0c36",
      "relation": "hasVariant",
      "source": 98,
      "target": 101
    },
    {
      "key": "88905dcaf316fafd54d6ac556028beb366a95a673c3bc102ca49fe43b6db25df6bd5af4f3ad10dedf7eef7e8d91877a80c2dec0f7e6620f2ade983427d108850",
      "relation": "hasVariant",
      "source": 98,
      "target": 102
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        },
        "Species": {
          "10116": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "It was later found that tau phosphorylation was inversely regulated by OGlcNAc addition in vitro, in tissue culture cells, and ex vivo in rat brain slices (Figure 4)",
      "key": "b739a320d7dd738d4577b53bf21a318a1d218fb3374a16b2662d90f253e56819c34fe806a91d967b33250d2a0542ef2b1322aee208a9c95745ac01f8688047cd",
      "line": 337,
      "relation": "negativeCorrelation",
      "source": 100,
      "target": 99
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Furthermore, downregulation of OGT leads to increased tau phosphorylation and onset of AD pathology.",
      "key": "3a5fd185e6181074b267f79dc77e375b435342d89198f70be8783e05ad4e869f92e178e0391889a323ca0954dd9f677ee255fb1811a6f5180d3a873b0660e44e",
      "line": 344,
      "object": {
        "modifier": "Activity"
      },
      "relation": "negativeCorrelation",
      "source": 106,
      "target": 66
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Cerebral Cortex": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Finally, AD patient cortical brain tissues reportedly have significantly reduced levels of OGT expression compared to aged and post-mortem delay matched brain tissue.",
      "key": "0aa55cee252f742b3709bca7c08270b59a1e230d94b81ee53d74fcdfa452cce16efa22ff39e0e5848cd6e36833a9a7bb20bb7444b03f59a5f724124392421254",
      "line": 369,
      "relation": "decreases",
      "source": 106,
      "target": 66
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Twelve-month old triple-tg mice (3xTg-Ad) displayed reduced levels of tau O-GlcNAcylation consistent with tau hyperphosphorylation in the hippocampus.",
      "key": "ddce99647d3b7de71d3ae9de521e32b0f1289dc82277dd74b90e17d4766601ddbfc2657ec57f8a55a8b1c99372ed8f6ddc2026fab405502825a87f91e4d515cf",
      "line": 351,
      "relation": "negativeCorrelation",
      "source": 86,
      "target": 87
    },
    {
      "key": "c3228644706c7d7254e5f83e1919fbf17e062d33a306d2013da465a94dd255fad572ace2b3c8ef855fbd587a7fba82aa854d3404d0dc03805da1b69adf6c5d78",
      "relation": "hasVariant",
      "source": 85,
      "target": 86
    },
    {
      "key": "f0be9855bf765f882e040f72ff4194fbe68fb934a20409df1f37665928cd5319c3b09c985e9843a2ecc6002610632713195f31b1e843ff4e1ed5611f95f539d2",
      "relation": "hasVariant",
      "source": 85,
      "target": 87
    },
    {
      "key": "b534fd9f3f746602fb748406ef4b5135a4ea2f5fa6346dd607bc73ff17e18ed5a8a2942e974a4f9a855d3991744e5f882cb5d7d84707906e50ee2c7a8aa21045",
      "relation": "hasVariant",
      "source": 85,
      "target": 89
    },
    {
      "key": "d187eddfa057d37d306253aea760ee6848ad2d39429ba367a63a2b2a2e6c1799a7f44fb446c5486199ae5765ee06886b66579a09a26beb7bae6166b37bf79abc",
      "relation": "hasVariant",
      "source": 85,
      "target": 93
    },
    {
      "key": "ee62c43bf8d8c6574e136fbd6c305a4c92a8bad7aa0cc5202b377cb29302b4b2dc75e76eec88a731a8f89ae254f0783d97c8ee971531f2f306a37e1eb0668cd3",
      "relation": "hasVariant",
      "source": 85,
      "target": 90
    },
    {
      "key": "236e073bbb571677b2ad9f7f80b447ada7dcb730abdc1d692dd2903d85d543a9acbc9dbec0da53221727d9a5f7df3e3aaeed7a4f34d272eb69c6e014dbf77618",
      "relation": "hasVariant",
      "source": 85,
      "target": 91
    },
    {
      "key": "f177ac97183e576dbee606fc7e8d19c6784616bf4f9f0efea20728a9ca1cedd2b404dfbeaabda7b632679871275e7708a1cc0c2ec51c597e5fc128f5d6d0c9ab",
      "relation": "hasVariant",
      "source": 85,
      "target": 92
    },
    {
      "key": "2c2ea9b1bf222f9bdc74a04eea4aea1ce45cab18586adb11e8c9889ab3c25edcd3db437e123224f5555bba399383b0c940ffbabee03881d8e5f45b8c2605a862",
      "relation": "hasVariant",
      "source": 85,
      "target": 88
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Hippocampus": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Twelve-month old triple-tg mice (3xTg-Ad) displayed reduced levels of tau O-GlcNAcylation consistent with tau hyperphosphorylation in the hippocampus.",
      "key": "07bdf3893ce5e88096a12a1c5b448451c679f855d1c176be8657ccc882cf1d9207de543c9dce2c154e056e3816655c4d7425b3634aca5e0ed1c5d86cbea8bf7e",
      "line": 351,
      "relation": "negativeCorrelation",
      "source": 87,
      "target": 86
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Brain": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gong and co-workers identified that impaired brain glucose metabolism actually leads to neurofibrillary degeneration via downregulation of O-GlcNAcylation.",
      "key": "0adc5430627c0270f2a0db92f0025dd7742dc4d64959b21036f20a9b0eea77e7fe8aa872201186929053e3180d490d41c5d55c8018c5263935e28568356a0f97",
      "line": 360,
      "relation": "association",
      "source": 27,
      "target": 84
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Beyond inhibiting its phosphorylation, the O-GlcNAc modification hinders tau oligomerization",
      "key": "5c4dad62314d3fcd034cc3482ab804356226c72ffe29bd1ba05e9b413326bc84ebb67509e8b16b72276cccf7bd8ba986339c709b626c3c05fdd81739b0427162",
      "line": 374,
      "relation": "decreases",
      "source": 57,
      "target": 60
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Beyond inhibiting its phosphorylation, the O-GlcNAc modification hinders tau oligomerization",
      "key": "4a0ca0d36ce72ddb3a18a70bcfaf50afe749b663503816c6bd669523aaa37b56709e8389fa44926da8466f1f5299c1768dbe0a7331af866289bbac96590c3761",
      "line": 375,
      "relation": "decreases",
      "source": 57,
      "target": 13
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Vocadlo and co-workers demonstrated that a recombinantly produced O-GlcNAc-modified tau construct (spanning residues 244- 441) formed oligomers at a slower rate, and to a lesser extent than the unmodified, recombinant control sequence during ThS fluorescence assays.",
      "key": "733034cd3bc9a710c6928c20375c4cd1e15e39e4d7e3c3d37ff849419eb11dc4ac654bcf953584e2f8443b883db50ab0f05c29903efa89a80b7384aa246fa5b4",
      "line": 381,
      "relation": "decreases",
      "source": 57,
      "target": 13
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Indeed, O-GlcNAc modification of tau-441 appeared to slow tauâs extension, perturbing the equilibrium position between oligomeric and free tau.",
      "key": "0c947cf0ec5d6399b0b252bf5f9d5ac801313233a9d2143eced9bb1bb5feba111ea73dee9146acd836f310e1881b04ec2af0ba0ecd51b9afd5d616b6e28de98d",
      "line": 387,
      "relation": "decreases",
      "source": 43,
      "target": 13
    },
    {
      "key": "bf95f2e6c76c12b6a32ecc154d47ec109037978f99c5b49715b04b749dca830a7b482c1cecd71dd132b6d21bb45744b1b333e43392be828a45e7098768caedfc",
      "relation": "hasVariant",
      "source": 42,
      "target": 43
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Results suggest O-GlcNAc modification at specifically Ser400 plays a critical role in hindering aggregation",
      "key": "d2f35b5a47518a3e59d18b1cd69d08aedfeecc8066471cc7d3b1d2eb94fa868094ae466525d85b007d5982ff095ae6adf5c445122a525be9e5be452bf896fab8",
      "line": 391,
      "relation": "association",
      "source": 58,
      "target": 11
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Results suggest O-GlcNAc modification at specifically Ser400 plays a critical role in hindering aggregation",
      "key": "5a967167565f7ee1c371eaecbb600005ad681e25da6bd667930cd17296aee297d1b095e2797e18a206b60f82603b3b8eb5ae5a9430e65b2313f3dad0024f2b85",
      "line": 391,
      "relation": "association",
      "source": 11,
      "target": 58
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gazit, Segal and co-workers reported that their synthetic, O-GlcNAcylated PHF6 analogue, besides possessing reduced self-assembly propensity, seemed to inhibit unmodified PHF6 fibril formation upon co-incubation",
      "key": "94e3faad7b667a3d233ccff592d5267e9ad5dad2cae468916961fb08e0fc8965a451f0d87810fe8161c77701b1d112fedf4fcbd21e4c331c84f40e8c595fc436",
      "line": 465,
      "relation": "decreases",
      "source": 45,
      "target": 37
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Gazit, Segal and co-workers reported that their synthetic, O-GlcNAcylated PHF6 analogue, besides possessing reduced self-assembly propensity, seemed to inhibit unmodified PHF6 fibril formation upon co-incubation",
      "key": "be42a0d736655c3bf8c4fedc18b9959b558a42ca94b656785575a3d6d58ff4b35c9db4d8e6d8c3e5958f7b79557cfe38f563d458334f894055db52d62df174da",
      "line": 466,
      "relation": "decreases",
      "source": 45,
      "target": 12
    },
    {
      "key": "835a8d13262ed7fd2ffacaf37ea63fc690cec8b4fbdbc1327600ad80dcc6a9388f74071024893f18ec9a775205dca3a263ad6fd07d83902e5a272d5be7579d8e",
      "relation": "hasVariant",
      "source": 44,
      "target": 45
    },
    {
      "key": "713df69a3246e187a123ce8bb9ab7fd0cf37caa35ad8a98df7bf8381e1e8c92a0de80170e3ea5e4a55a8758bad74dc8a846b11a94bfb3465c7248e1e27565169",
      "relation": "hasComponent",
      "source": 37,
      "target": 44
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "An inverse correlation between O-GlcNAcylation and AÎ² formation was reported",
      "key": "648cfe2a4e2fbabe4a4116fd4e69ed2701f1f5a34a5bf9e26c9e72a2a77eaf1d6574ddbef5225815eb8a1700dc810867c34a0576eb71a92a629b4f2f16f384be",
      "line": 482,
      "relation": "negativeCorrelation",
      "source": 51,
      "target": 1
    },
    {
      "key": "50c1f00207a790bead8332b72a5c54bc452ac8cd60f9aacf47aa77f0952d8bc5cb908c1c73f430488adfe5d4b16d9dcc816bd4d0a208946fd07a11970686d94e",
      "relation": "hasVariant",
      "source": 49,
      "target": 51
    },
    {
      "key": "b30d71e25b64f22341dc7e78130ecbf18a3dd2e0f58676c3d03a4d1fab8814a2d807ddc05cae302c7d0b860b755f1415b0cbcfe3efc70e0de2c4954558765387",
      "relation": "hasVariant",
      "source": 49,
      "target": 50
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "An inverse correlation between O-GlcNAcylation and AÎ² formation was reported",
      "key": "bbc12fc3435f2218cd7036a1956258e66246eafeac10ab73a3ba8c8738aa776847818d8fe96a65007575d4acc5feb7fe93d64ddeeeab3e8576a0e8ece6b00038",
      "line": 482,
      "relation": "negativeCorrelation",
      "source": 1,
      "target": 51
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment of tg TAPP (tau/APP) mice blocked cognitive decline paralleling decreased AÎ² and plaque levels while not affecting tau phosphorylation",
      "key": "28551c49cefbb8e141e1243c38b97abcca5810c137acf99c8e4a9445bcb4be2bdfce13e9082e01d5ed475b70c10fdc26c65bd54f62634fede3f3a7e82e9ef71f",
      "line": 512,
      "relation": "association",
      "source": 1,
      "target": 33
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of the 5xFAD AÎ² mouse model with NButGT, another studied OGA inhibitor, impaired AÎ² production and attenuated activated gliosis",
      "key": "2be92913f709771bac2b2bdce91c069b7ebab24e4e792d3facd167fa51a8900391642e8c2a27de43297c36d827bcb77dfd45a1bd6c405a0b808500e580543516",
      "line": 487,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 18,
      "target": 65
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of the 5xFAD AÎ² mouse model with NButGT, another studied OGA inhibitor, impaired AÎ² production and attenuated activated gliosis",
      "key": "bdfe4b10b32afd3dd34d74536a35cc7e67d401a4a23bf9650a9455fad51bcdfeaa0d461c1547dcd75fddb7afc108c6b1868d46b62e0a32893e3ff4c20d12322b",
      "line": 488,
      "relation": "decreases",
      "source": 18,
      "target": 1
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of the 5xFAD AÎ² mouse model with NButGT, another studied OGA inhibitor, impaired AÎ² production and attenuated activated gliosis",
      "key": "c550ab0908f923f8b543a53522c4475c7e35078c5247f492ab0e6af0cc895961b1554c779514e43723f6d1991e3489b4ed668ca734ceb0bba13d2a8ed5ee1c66",
      "line": 489,
      "relation": "decreases",
      "source": 18,
      "target": 110
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Spinal Cord": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Treatment of even the mSOD mice with an OGA inhibitor, NButGT, increased levels of O-GlcNAc in the spinal cord.",
      "key": "e23fd331e639fe65622166f20b925e2eaf58b28b81c491aa2cdfcfe61c8c9b7a9ad7dee86b7059bbe9c6150a269f0ced9537cd9ceb57485828504b7d233a88ee",
      "line": 569,
      "relation": "increases",
      "source": 18,
      "target": 96
    },
    {
      "annotations": {
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Thiamet-G treatment of tg TAPP (tau/APP) mice blocked cognitive decline paralleling decreased AÎ² and plaque levels while not affecting tau phosphorylation",
      "key": "1821badd1ffa410f82ac214bb8147a17f924c1be76fe866e5fcb3f1a136466319ad47c81cd6cf9d640de81e297b55f7be7dd88e2ea76b0d3851d0925134275ca",
      "line": 512,
      "relation": "association",
      "source": 33,
      "target": 1
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Finally, treatment with prostaglandin J2 (PGJ2), an endogenous mediator of inflammation that promotes cleavage of secreted APP, is reported to increase overall levels of protein O-GlcNAcylation.",
      "key": "99dd48e2d82fc55425444a3df584c07a4cb02fcd1db69460bdeea8194683ed0e6c49a1df5dfebdbf1bb69fb1e38afccc0ea4dba0f4b03606ffb0538ab72c7dfe",
      "line": 520,
      "relation": "regulates",
      "source": 2,
      "target": 113
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Finally, treatment with prostaglandin J2 (PGJ2), an endogenous mediator of inflammation that promotes cleavage of secreted APP, is reported to increase overall levels of protein O-GlcNAcylation.",
      "key": "7c703f1a0a9763113cc8a3560fbeb92714ee32be28f76eee82f345f2845137fdacf9b373c5f51400735529b59295ee3aa09fb2b5085d7f62aaffc42de9868975",
      "line": 521,
      "relation": "increases",
      "source": 2,
      "target": 50
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Finally, treatment with prostaglandin J2 (PGJ2), an endogenous mediator of inflammation that promotes cleavage of secreted APP, is reported to increase overall levels of protein O-GlcNAcylation.",
      "key": "d000649569c5799e7a98d50817f3f9c25cec0dcbc17648cdeac04083988ebf977973a95586bd765a14d52cabfc1e60e0c1590069ce6a3a30437a9afa0ee8f7da",
      "line": 522,
      "relation": "increases",
      "source": 2,
      "target": 51
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Normal huntingtin plays a role in vesicular transport, transcription of neuronal genes and production of brain-derived neurotrophic factor (BDNF), besides potentially also possessing some anti-apoptotic function.",
      "key": "c40bb7b97e95ed763c5f0c7e3bc6446fd64dd14ef49eac708da4372ed6aa39a54207bcd819b235fff8f1dd25865562e4f3d35f24353ec2e971d6430a5edeb4a3",
      "line": 529,
      "relation": "association",
      "source": 53,
      "target": 31
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Normal huntingtin plays a role in vesicular transport, transcription of neuronal genes and production of brain-derived neurotrophic factor (BDNF), besides potentially also possessing some anti-apoptotic function.",
      "key": "9dc159907504aca6201471b56e79633b730dc72f8aee6668ff59402b13907f54866771c53e65cadc5ff2c2953c5ebb240e60c6de4fd6c4a571446627f6b27c21",
      "line": 530,
      "relation": "association",
      "source": 53,
      "target": 52
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Normal huntingtin plays a role in vesicular transport, transcription of neuronal genes and production of brain-derived neurotrophic factor (BDNF), besides potentially also possessing some anti-apoptotic function.",
      "key": "b67c3656463b25122f44ffd2d10e01db9879fab7ba8a564992157d82f04cac920854f63d931f11b342f61083be36c8a6601bccdeb17a77a0e96ee7534d2a5290",
      "line": 531,
      "relation": "decreases",
      "source": 53,
      "target": 23
    },
    {
      "key": "12aa2a7c2ee5f67a68ff368525394357e9750233fe1842650bd53ff1ce1638f34894883c10c75b0ae7ff6e092b9ca96753a88315fcbc6cf975c7d2d8721e8cea",
      "relation": "hasVariant",
      "source": 53,
      "target": 54
    },
    {
      "key": "a3ac61ee6ec4e9b3af47845dbe04b3de658393e1d87be866f3fc491ce0722391f8d21e748e8816d98859b534dff8a41ea1d7df7603199741e1d45d50c1675f96",
      "relation": "hasVariant",
      "source": 53,
      "target": 55
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Normal huntingtin plays a role in vesicular transport, transcription of neuronal genes and production of brain-derived neurotrophic factor (BDNF), besides potentially also possessing some anti-apoptotic function.",
      "key": "fcf8ac3b9fbde470c121b909975b16cee6b68ab81ad7ab203801a41a56400c1629bccc7b367aa9ee29080da778267509fdcc52ec284bc811c11837963355dfab",
      "line": 529,
      "relation": "association",
      "source": 31,
      "target": 53
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Normal huntingtin plays a role in vesicular transport, transcription of neuronal genes and production of brain-derived neurotrophic factor (BDNF), besides potentially also possessing some anti-apoptotic function.",
      "key": "bff87fafa9fc55a1092ed376bfa0066a0fcc7c80862cf6a025aca6ab5be49b0feb5d1026727c8cfd5575475b20360f9f8d6c2d8660a6011e7399b7d77ed36d2a",
      "line": 530,
      "relation": "association",
      "source": 52,
      "target": 53
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Instead, decreases in global O-GlcNAcylation levels is reported to be protective against huntingtin aggregation and cytotoxicity in neuroblastoma cells and fly models",
      "key": "bbecb38b11c2b4a2aee8d93d40bb205e30449d807a2d7b93fa2218d6475043bf43186a2aafca38df14103e706113f4cfc136ddb839cb1f7ea24ca0a1e0eb0f96",
      "line": 536,
      "relation": "increases",
      "source": 54,
      "target": 17
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Decreasing O-GlcNAcylation enhances autophagosomelysosome function, which leads to increased basal autophagy flux and clearance of toxic huntingtin aggregates",
      "key": "c3385f8d13f5d84cdd561544eb776a74cc980c5565726fb5563daacef4767a0d2dd7206fd499345ecd7d0174d04dcd0f71cfc1beb979520f535d3ef154c003a1",
      "line": 542,
      "object": {
        "modifier": "Degradation"
      },
      "relation": "decreases",
      "source": 54,
      "target": 17
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Decreasing O-GlcNAcylation enhances autophagosomelysosome function, which leads to increased basal autophagy flux and clearance of toxic huntingtin aggregates",
      "key": "c2d6973c434a07dc7cef4ec948598aa0b0c80703ef6e275771a90995c248a347cbcb4f935e6222dbfed6e7f5b6d3d21c16e7108959ead84c52785d168a24b4e0",
      "line": 540,
      "object": {
        "modifier": "Activity"
      },
      "relation": "decreases",
      "source": 54,
      "target": 8
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Decreasing O-GlcNAcylation enhances autophagosomelysosome function, which leads to increased basal autophagy flux and clearance of toxic huntingtin aggregates",
      "key": "ec0589dae787fa3646e57154cc356cc0b57c626dfbd8c41fe7f2c0922cd46db9913ba4b31a1b9a169e15217cefaad3879d970cdc260031140963299e5bb22dfd",
      "line": 541,
      "relation": "decreases",
      "source": 54,
      "target": 32
    },
    {
      "annotations": {
        "MeSHAnatomy": {
          "Spinal Cord": true
        },
        "MeSHDisease": {
          "Amyotrophic Lateral Sclerosis": true
        },
        "Species": {
          "10090": true
        }
      },
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Mice carrying a mutation in superoxide dismutase 1 (SOD1) also exhibit decreased OGlcNAc levels in the spinal cord",
      "key": "7fe1c02f522c551920b61f0b2d591855876a2bc9c18db9985b81ed8573f809867ca13804f1e8df209c6ecbf4ab666bad4cb073360419f8a3a765521dc6308652",
      "line": 555,
      "relation": "decreases",
      "source": 97,
      "target": 96
    },
    {
      "key": "354c324604cb85b588ae948467ce5a25f65a599fffae101ea39986bc8f685c9dc1a0039cb5447098220b6c03ef558e3b43b659a141adf56664ac1906a3877770",
      "relation": "hasVariant",
      "source": 95,
      "target": 97
    },
    {
      "key": "ebc20e7469de8a610d4d419a35bd276e1926c47c115899e169181925f10b9695ac65bf1433f64aa59a44e8ddc2d2513397e115c51989a576cb4f5d018c2e1032",
      "relation": "hasVariant",
      "source": 95,
      "target": 96
    },
    {
      "citation": {
        "authors": [
          "Danon JJ",
          "Davey AK",
          "Kassiou M",
          "Mellick GD",
          "Rudrawar S",
          "Ryan P",
          "Xu M"
        ],
        "date": "2019-04-26",
        "first": "Ryan P",
        "last": "Rudrawar S",
        "name": "ACS chemical neuroscience",
        "reference": "30985105",
        "title": "O-GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease.",
        "type": "PubMed"
      },
      "evidence": "Familial SOD1 mutations are responsible for 20% of familial ALS cases in humans",
      "key": "3034b6c06e9bcf60a9a6965d0e3d95921740253d5d7bd494c4a1d967ae950d7b60adb78f11eed7d485adc045e2b637d8097a8ae743b1b661531ec4d3d68056dc",
      "line": 562,
      "relation": "increases",
      "source": 80,
      "target": 107
    },
    {
      "key": "ac635f17f31ec93b9300cee1d38cdeeed57dee8049983c025a490f45198a7ce226ce24152230546583247d61980363aab127361f19888b49910296c9d4b46dbb",
      "relation": "hasVariant",
      "source": 79,
      "target": 80
    }
  ],
  "multigraph": true,
  "nodes": [
    {
      "bel": "a(CHEBI:\"amyloid-beta polypeptide 40\")",
      "function": "Abundance",
      "id": "2ca2eb795438fe9e0f24c1e9d332717de5e344ddfee00ce8df89c5b901d85db5994d6ffd383e40a90bde264f33e75b220476b3de86c89f0658bf281c872f0bb6",
      "name": "amyloid-beta polypeptide 40",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"amyloid-beta\")",
      "function": "Abundance",
      "id": "a9487b29439483c6840095610dd3e496e3ca9cccc3a8d71e0385a39b570f3c0a26965ac06d83265e1c08deaae7998272d4f4c21ec0534f8be3fd8e4e57dbb3a2",
      "name": "amyloid-beta",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:\"prostaglandin J2\")",
      "function": "Abundance",
      "id": "f6b5858083f34929d007ae8bbc5fac382dab059176c715b143f8c923a9b35bcdd30d96c0e1982a65115f9624f19cf0ecdf42ee77162f8153f38aae80702cb875",
      "name": "prostaglandin J2",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:glucose)",
      "function": "Abundance",
      "id": "ad228f723834a0438254651fae75410bfa5cb8ee6d9baa98af0240115b1e5ec55edb5d001429c764d8785ec034b6b90edc76a4b83d14572cae3624feacf85491",
      "name": "glucose",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:phospholipid)",
      "function": "Abundance",
      "id": "059b31b0fcdfbb214b0e54d633c669f863f64083c7c8f10e294c0a7ce61e436804ab8d9283481a98ea92c40aaea4b3ff4aec7a95824a8f4a292bd2094f75eba4",
      "name": "phospholipid",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(CHEBI:sirolimus)",
      "function": "Abundance",
      "id": "102b031a00eed78fd9e5c4236defb90a8995463980f9060493bb5fd3159a3eb666cbb2b6a33a213c749a2b279ef6d149796b4f0b568e03b82eb5c89b0da77426",
      "name": "sirolimus",
      "namespace": "CHEBI"
    },
    {
      "bel": "a(GO:\"neurofibrillary tangle\")",
      "function": "Abundance",
      "id": "3b50c674ff9633f408e5173562a06cf3a856abc95a8b034db8e940b464f1cea72df6f9fa9b7b02b5daf4eb86a37a155f203289451f7203a7b9c9e6c65313eadf",
      "name": "neurofibrillary tangle",
      "namespace": "GO"
    },
    {
      "bel": "a(GO:\"synaptic vesicle\")",
      "function": "Abundance",
      "id": "d145f42b1cf3732a644e504e8c09e68f21a2a7456136505a45e9eb8938e9f8279c86b95caa6feb96f8aa2d4771f263ca1f9820bd13f66df04f9ea377f1581406",
      "name": "synaptic vesicle",
      "namespace": "GO"
    },
    {
      "bel": "a(GO:autophagosome)",
      "function": "Abundance",
      "id": "715a4a43d0864573b89131b448d7cc46791ca779974c2ada17b881dda1dcdf4e67fc60a7c5d777ea65d035c51f0048585689c1917866dc437cb2e24c943a61ed",
      "name": "autophagosome",
      "namespace": "GO"
    },
    {
      "bel": "a(GO:microtubule)",
      "function": "Abundance",
      "id": "0c753f37efe0eb149a47a1dd700eda093a03b462374275c68480b6aed3be0f81aa9793a179dfd97f8e0834f1fb9be4b4a6cff2165b176d9e8a8744f5e0d5bc2c",
      "name": "microtubule",
      "namespace": "GO"
    },
    {
      "bel": "a(HBP:\"Dopaminergic cell groups\")",
      "function": "Abundance",
      "id": "f092c885a197b32deb67d775fea84a816071f7f99e0e66f7fc71789d6e1ccf3e489bb642e718d772f5c5a1bfba35341d382ea322b1582c41157a1106a7f788cb",
      "name": "Dopaminergic cell groups",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"Tau aggregates\")",
      "function": "Abundance",
      "id": "2f93b798e33773ea9681389870bbee41f6fa7ee04c087bda4bd1492520385f58d089a7261b1353e15c31d3e29a96ff31884886e6ab9fa477ef8f63f19cf154f7",
      "name": "Tau aggregates",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"Tau fibrils\")",
      "function": "Abundance",
      "id": "cd2dab27f628336ca0ed44605c7cd92f2fd119b914305cba845b06c61ab768ecf96cc32e4679b8ca5361f3e5cd3bd2418c91526348cc067d58282b812be1310a",
      "name": "Tau fibrils",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"Tau oligomers\")",
      "function": "Abundance",
      "id": "d4ceff8aa5a5d05770aaa29b828d003b85d64e7e5337c6624b7c5a84111845897462b589e7b259b0eed6bcfc63f34cdaf1f9b988c788804799aea026d8731d98",
      "name": "Tau oligomers",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"alpha-synuclein aggregates\")",
      "function": "Abundance",
      "id": "4ffe86a09eab120b36e016ef7b19c9d01be6656ede07fd078714196fcc814ae0586e60fc52bb1a087f53639ba2004c175d46d511472d216e386711c2d05dcb21",
      "name": "alpha-synuclein aggregates",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"alpha-synuclein fibrils\")",
      "function": "Abundance",
      "id": "e7d37ca7db3a392fb57741b397c3d2a199341ad03918944c91543eee061dbff1f594f28a341323fa8d0501bcbb8aa00baf48f75c055a2cb8e62d899d73cbc101",
      "name": "alpha-synuclein fibrils",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"alpha-synuclein oligomers\")",
      "function": "Abundance",
      "id": "64c75f85509685303ba078d6cd796e192c764fd9b8dbc7486d4eea94b534574fa9d0ab0c588872bd8abb5d8fbea1c82f593ba18dffe002cc6e8fee2ef0131af8",
      "name": "alpha-synuclein oligomers",
      "namespace": "HBP"
    },
    {
      "bel": "a(HBP:\"huntingtin aggregates\")",
      "function": "Abundance",
      "id": "b002c83453fb9ff3e295ad07a36f9afee91ab00c52c321dee1b31e9b1ae80e79109adf64b9b235ba967d89545d80f66dbe86856bd4751018f2e0bf2c07ff477e",
      "name": "huntingtin aggregates",
      "namespace": "HBP"
    },
    {
      "bel": "a(MESH:\"1,2-dideoxy-2'-propylglucopyranoso(2,1-d)-delta 2'-thiazoline\")",
      "function": "Abundance",
      "id": "83a00a7050ab0c8a7b8732b2fb8f2c3cfa96fa003248b3166cb920ff2f58ac5f6807b2155a1be36b23294039234366f23dc17fcc1618b5e9dc614a6086e6ee2f",
      "name": "1,2-dideoxy-2'-propylglucopyranoso(2,1-d)-delta 2'-thiazoline",
      "namespace": "MESH"
    },
    {
      "bel": "a(MESH:Hexosaminidases)",
      "function": "Abundance",
      "id": "9bc1d10e643534a98bce1fcc5e2cb946f15c3ba187596190733b557bc99de4f873ffb7769edc7227d27777ace4ff5e1b64f848300829efea82c2070307d2dd2b",
      "name": "Hexosaminidases",
      "namespace": "MESH"
    },
    {
      "bel": "a(PUBCHEM:135566354)",
      "function": "Abundance",
      "id": "d40a1eb941f037ccf4bc396777654ac58cb3c20883284510103cd2d78d3af96398b935b28a4f1e4ba8f83f2727abe87fa53af25d3b3d73a657f3a326a2d7e1cc",
      "name": "135566354",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "a(PUBCHEM:9576811)",
      "function": "Abundance",
      "id": "9e3a7b7200a996efdc5df44b5743b0bb05cd3bd1f12a3f2353eecc1f1daf66bde0397fdc2d429be23627821b655eb39e744a01cf9b564f12190b8027a2af0e87",
      "name": "9576811",
      "namespace": "PUBCHEM"
    },
    {
      "bel": "bp(GO:\"SNARE complex assembly\")",
      "function": "BiologicalProcess",
      "id": "9506343118b89e3c2d0f6096737619c09ae10443020ba8824d5c042ed7464f007435e93f03b8eefcdc590601c7efaef863b3a8fac45866e006426f88ee882124",
      "name": "SNARE complex assembly",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"apoptotic process\")",
      "function": "BiologicalProcess",
      "id": "1c5172472cbecf29eeb8e86a4cac2d13123fe572356f00e2f98302422560bbda2854e3b1f8fdf85396655393cf5ddb42e0db210c3d3fc146fa358cc8d0ed0254",
      "name": "apoptotic process",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"brain development\")",
      "function": "BiologicalProcess",
      "id": "25cc1c3cfa4fc89f3429743927ae418ae3277146e10022e0b21235bc54289a2eb4b4d561714971be822191f1f1b17e9a5de5e34d1031284ca59c2eb0240daf7d",
      "name": "brain development",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"cellular glucose homeostasis\")",
      "function": "BiologicalProcess",
      "id": "fd1ea74b3d643a32c1795368d5c769f47e0fedc70d256f41aefbd79daef4b50df37e2629efc39d0bdfb904da08a8e1fe83b5f1a959a3fa84528c6bde3ad25bdd",
      "name": "cellular glucose homeostasis",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"dopamine secretion\")",
      "function": "BiologicalProcess",
      "id": "677a4a705049f2c365df0ce1891506f776505e8e9936b96c1a6dbae1fbfac951848b0de2762d7bcfdb5b6ac451251927ead172a83d29522d73c4f0b51801010c",
      "name": "dopamine secretion",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"glucose metabolic process\")",
      "function": "BiologicalProcess",
      "id": "6681cf02278d39bd743eb5de75ec62487ae3b5c20d67d093d8eac248b88f7f481874541876ec7942d3430b054ebe491b1737e811ade8aad646f60cc638344ac1",
      "name": "glucose metabolic process",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"motor behavior\")",
      "function": "BiologicalProcess",
      "id": "181472b7f9a4b32696b87492619020f88bad9e24f439e97158614801e3fb1dda434c97b95c252baa65a43ba7d78eecfca26f91f6a5295d37b21e6873f04a73f6",
      "name": "motor behavior",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"neuron death\")",
      "function": "BiologicalProcess",
      "id": "ad7c90f2bc746a5118759fd1c8857478c02207d574a26faaac9d6e4d6fa4661d8d87446139db0024a4011aae26027d3cabdfba663aec0ac0a8242868efb81dcd",
      "name": "neuron death",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"protein phosphorylation\")",
      "function": "BiologicalProcess",
      "id": "abf09aab1363aec3089a1380f7ed21622b29ab8fa39c40dd6e8587bf8a250812887e207483b9da6d7e6a848daf919cfa3e76ae11ed4ab1014ec442e014b30a4d",
      "name": "protein phosphorylation",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:\"vesicle transport along microtubule\")",
      "function": "BiologicalProcess",
      "id": "aa364cea64268b9c78bbedb52486cea7fd1c58af6ffca221feca1b3af6294d9024e724c3594513eb36b362d3e588ed0daa05d4c3e5c2cc27aa0bce4906c6a23f",
      "name": "vesicle transport along microtubule",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:autophagy)",
      "function": "BiologicalProcess",
      "id": "f1a3202be460e565f65c1445ee061e99f63cc05f9ab70c5d4d8d93ba180d6a94f65cb8d1ac6c5ba53c0a4d2e153db32135e6a0bffcfdfd4d84e6727594a70b0a",
      "name": "autophagy",
      "namespace": "GO"
    },
    {
      "bel": "bp(GO:cognition)",
      "function": "BiologicalProcess",
      "id": "8d73f2caa1c473289d5f37cbdd4ad391a120cdbdf2356b373070c2a7b2bc0c785eaa620782fa2dd947c666100f0a169e81f35864f359cadf3e1550962fcc4127",
      "name": "cognition",
      "namespace": "GO"
    },
    {
      "bel": "bp(HBP:\"APP processing\")",
      "function": "BiologicalProcess",
      "id": "cfc9433284818feeeee20158891cf4f5b802c0ba463538840e389a3a97739446bff7305190f4a55ff4f6b3667531d853072705d9596122d30d2fc382eb77720b",
      "name": "APP processing",
      "namespace": "HBP"
    },
    {
      "bel": "complex(a(CHEBI:phospholipid), p(HGNC:SNCA))",
      "function": "Complex",
      "id": "37f4e78f4e1a19554d32aaac6fea66dffac068e498965a385b655245016ee0a7fee1451d8be8f0d9950b4a858cbb242b7349f92208217146aa6f01b9bdf9da38",
      "members": [
        {
          "bel": "a(CHEBI:phospholipid)",
          "function": "Abundance",
          "id": "059b31b0fcdfbb214b0e54d633c669f863f64083c7c8f10e294c0a7ce61e436804ab8d9283481a98ea92c40aaea4b3ff4aec7a95824a8f4a292bd2094f75eba4",
          "name": "phospholipid",
          "namespace": "CHEBI"
        },
        {
          "bel": "p(HGNC:SNCA)",
          "function": "Protein",
          "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3",
          "name": "SNCA",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(a(GO:microtubule), p(HGNC:MAPT))",
      "function": "Complex",
      "id": "d7f2684793c3c1a57485b55fb8f794739e78d15404986239556841672a48127c8ba3d10a4d9c685163f7442d36972062fdc0329cb3373c4d2cc787e67c185da0",
      "members": [
        {
          "bel": "a(GO:microtubule)",
          "function": "Abundance",
          "id": "0c753f37efe0eb149a47a1dd700eda093a03b462374275c68480b6aed3be0f81aa9793a179dfd97f8e0834f1fb9be4b4a6cff2165b176d9e8a8744f5e0d5bc2c",
          "name": "microtubule",
          "namespace": "GO"
        },
        {
          "bel": "p(HGNC:MAPT)",
          "function": "Protein",
          "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
          "name": "MAPT",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HBP:\"VQIVYK motif\"), p(HBP:\"VQIVYK motif\"))",
      "function": "Complex",
      "id": "ed51b488ddd9e637d6707b0ecf4e6f8e9e3b229adc2c340d51e357ae12cfbbb1b5373519cd09398d77d77430a2fb024bcd8fc16507790966ff69ae3d7433466f",
      "members": [
        {
          "bel": "p(HBP:\"VQIVYK motif\")",
          "function": "Protein",
          "id": "d24410c0e1f7134ec904e57582699c3206010f0f52b68cbe7c0703edf4c6ef1628720acd2447aa7e65fa67801ba3140fdaea3a4b1e60d7e5ada7a737c830869e",
          "name": "VQIVYK motif",
          "namespace": "HBP"
        },
        {
          "bel": "p(HBP:\"VQIVYK motif\")",
          "function": "Protein",
          "id": "d24410c0e1f7134ec904e57582699c3206010f0f52b68cbe7c0703edf4c6ef1628720acd2447aa7e65fa67801ba3140fdaea3a4b1e60d7e5ada7a737c830869e",
          "name": "VQIVYK motif",
          "namespace": "HBP"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:SNCA), p(HGNC:SNCA))",
      "function": "Complex",
      "id": "5b43376ec207b0b31069e8151607916f4a021de33f6633cdd5f0e71bd4b88d9fa2e9a1eee4e9518a0e99341e697a89a08ca9a67af082ed9eb31656d60d4daf32",
      "members": [
        {
          "bel": "p(HGNC:SNCA)",
          "function": "Protein",
          "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3",
          "name": "SNCA",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:SNCA)",
          "function": "Protein",
          "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3",
          "name": "SNCA",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "complex(p(HGNC:SNCA), p(HGNC:VAMP2))",
      "function": "Complex",
      "id": "a7a7ff4e20f2a6171510eb4c614db111506652f1e95b3c8c9a65044c0bd6074a4def5e012ae16060fcb89bad8d23291c4c2c8d9adcd60df440bc99163ffd0d7f",
      "members": [
        {
          "bel": "p(HGNC:SNCA)",
          "function": "Protein",
          "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3",
          "name": "SNCA",
          "namespace": "HGNC"
        },
        {
          "bel": "p(HGNC:VAMP2)",
          "function": "Protein",
          "id": "6c818f2d1362dbe865916238b9aea3c674022e87405ca8d0885ca53bbed181fa985f4210f8e45ae315b34295961a08e888279c8dfcf1ec556278c702fbc342cf",
          "name": "VAMP2",
          "namespace": "HGNC"
        }
      ]
    },
    {
      "bel": "p(FPLX:AKT)",
      "function": "Protein",
      "id": "3263678a1e320013081e7134e7e64e91b2c66e6fbd10dd7fe4fd282cf0cc3ba29b5cacb5e8eb0a8ac0a194f73b80dabcea5465b0fec5b044290b259ba889cef1",
      "name": "AKT",
      "namespace": "FPLX"
    },
    {
      "bel": "p(FPLX:AKT, pmod(Ph))",
      "function": "Protein",
      "id": "e0ee1c0157a2e80e92de9745508ee6e818136d101d39c7f9a2c0a61ce4155bb1dee984ecee4d3f153cee55b87c5821b182f32bf6c394fb20beb507e6b337499d",
      "name": "AKT",
      "namespace": "FPLX",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HBP:\"Tau isoform F (441 aa)\")",
      "function": "Protein",
      "id": "6f77e66c8e6368b067f47a9e99af43c53de45b1decba4c781f56e3d00bc2250510977965c81031b9b64a3e71da16a521a52f27bb16fd9846d5816bd36abd9ee7",
      "name": "Tau isoform F (441 aa)",
      "namespace": "HBP"
    },
    {
      "bel": "p(HBP:\"Tau isoform F (441 aa)\", pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "d87f5ae6017561015d68d0a2c2904ca8ef88e5ba248620e4871fdaeb32e7ffa78ba1bcb31b933df1ccd60c3661cc4bcb813993818dd363d556b08564cd5cb0fa",
      "name": "Tau isoform F (441 aa)",
      "namespace": "HBP",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HBP:\"VQIVYK motif\")",
      "function": "Protein",
      "id": "d24410c0e1f7134ec904e57582699c3206010f0f52b68cbe7c0703edf4c6ef1628720acd2447aa7e65fa67801ba3140fdaea3a4b1e60d7e5ada7a737c830869e",
      "name": "VQIVYK motif",
      "namespace": "HBP"
    },
    {
      "bel": "p(HBP:\"VQIVYK motif\", pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "42d80520efbcca75a2e3e50702da9a8b9442af6086f08ec0c7dbf0ae7c6b4fcf568c4b3d378e44ead471b40bba4b4af94451dd823e1325ccdee64ca569af5993",
      "name": "VQIVYK motif",
      "namespace": "HBP",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HBP:\"alpha-synuclein fibrils\")",
      "function": "Protein",
      "id": "567b2e9dac999402cd325da32d9ba239ae7a641ace9d3e66db7f39a8a4cae7acf52962979da6a04866d1ae1dd86d70155b28454a9b1eeee1f33af8c7907d5743",
      "name": "alpha-synuclein fibrils",
      "namespace": "HBP"
    },
    {
      "bel": "p(HBP:\"alpha-synuclein fibrils\", frag(\"?\"))",
      "function": "Protein",
      "id": "aeff620842ff7b2f36291bf1f0df2a30d9036028470625eecef8cddb407c28a15827379e9d2b836730b5121b8e5a12dd2f7eee9ce62b849ce139fb8a10068750",
      "name": "alpha-synuclein fibrils",
      "namespace": "HBP",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(HBP:\"sAPP-alpha\")",
      "function": "Protein",
      "id": "418c49e0c3ffa3351f60cd21b4b10a7b0350af5edd981d17c3abd3d60a03d9e431358632bfd8f8921627ff026ccddce4156279ef19243074e88cd4a76d940322",
      "name": "sAPP-alpha",
      "namespace": "HBP"
    },
    {
      "bel": "p(HGNC:APP)",
      "function": "Protein",
      "id": "ed1d45f3255226e4210017e6c179950e0e04a300727326d7fea6a9659868e8818ff64fd5e8a2a92a703fb1566b3f48323750ac6c28e7adb40843053d276710bc",
      "name": "APP",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:APP, frag(\"?\"))",
      "function": "Protein",
      "id": "0cd030feee61d24509f1113cd1a21235abc2d2ea5e708eee393187b282274b4611a6b84fbe441e827bb24baad54f8701bd724f8fc4439f01f041368f8783abf8",
      "name": "APP",
      "namespace": "HGNC",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(HGNC:APP, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "98053649fe2fe46ef164d605dc822fdb39fc358f244b0084036a180b7e49681ec21b1a3e10372c6e782946dcb06709041744aab3479f6e20626b9a8542ac23dd",
      "name": "APP",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:BDNF)",
      "function": "Protein",
      "id": "5bbeeb6a1045d125bd5495fbff1f4831c8697d0b4f9b77ff9f1127fd8bcf4d96eda74adab4e84332c6c9ba5bb97e102771278841e902a126ddbb438fddf7b8be",
      "name": "BDNF",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:HTT)",
      "function": "Protein",
      "id": "f3dac0d39a258f730f45800014166f0cd6e8002b0bd1f9be6aefa0958d84dc3a67a48721743405568d2c7942ea831f7bdc6cdcc7a990bb1a7d5161351e6e67b0",
      "name": "HTT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:HTT, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "5d43aa6fa7149cedd8eb291bbaa9e8f23bb3105191a5be5e52dbb34219869a85d83cbfcd2b05c1daffcecf28c3346f7f6211cc86e3e56ed01a8d38082d55242f",
      "name": "HTT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:HTT, var(\"?\"))",
      "function": "Protein",
      "id": "ecfea6b35e9ef56154b1f7d1255c3ae63e48c14c262428a01170245d2ffae3786b0b2439c3b2b1f6abf506d5ff2a338d6de2d7a2c18ee7defc89d51c50e22f75",
      "name": "HTT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT)",
      "function": "Protein",
      "id": "ad82d360f02888e890bb2d1f91d1dc020c21cebed2b4eed0193a58e6b396b5f0797d607568dea382c05ffe2a003537d10190b020739af8d51c8d7dbc19bf5ab1",
      "name": "MAPT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MAPT, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "540b2c8483c571637a5144c6e10212577f9e9a2bb06cc332c8559c23992505bc78e695980e3b3a95bd29245afbe8cfac4a5b6c101b3d4c83c66123e6e424728a",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(HBP:\"O-GlcNAcylation\", Ser, 400))",
      "function": "Protein",
      "id": "ead862a9ce0a2722a1608fada83714fdb68bbbca264411cd10a096045b4df609951280dd94eb0c6a2bcb4c24ac2895f563bd7e6380e8670b834f2e213211c4a8",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 400
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(HBP:hyperphosphorylation))",
      "function": "Protein",
      "id": "ede67fb639f29861d91976fefa16d8279b53ae13a659f35d70ed12e01bf3f339ffcf701fc54c7c4e908fee9902c02aac3e0022dcae5a7afa217ed2d4dba133b0",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "hyperphosphorylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph))",
      "function": "Protein",
      "id": "526bae251987f8c4f55f6e2451662fa55e087c57585beae7c389b020d73487c739834e9b8ec841783de6a5b5fb9df8b138e9eff4406a9ec5e606766575dcac0e",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Ser, 396))",
      "function": "Protein",
      "id": "233ebce30d7505cee42acc956f9d268e5b725e14853bd56fab3b87a93a4e0c8141a6fdec062d10e9c4924f6e13a61184600872c2f5080656e3ca27227eb4cb93",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(HGNC:MAPT, pmod(Ph, Thr, 231))",
      "function": "Protein",
      "id": "fd67fbe5c0c0911e8bffaf415eb40748a781d8776f2e2cdf8a3f4f97f0f2f312aaa680c7b670dc27b11d220f0079b4d5e41cbcf095a568bc644b6e9eaefc50b3",
      "name": "MAPT",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 231
        }
      ]
    },
    {
      "bel": "p(HGNC:MTOR)",
      "function": "Protein",
      "id": "4295eeb1bbce42b573aab8558d259ce748cbe0e654d937c271988dcbccadf88e9ca956ccb7b3c3b1e44d70554b4f4a54e83eec0d411d6ef25631920ca14f6789",
      "name": "MTOR",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:MTOR, pmod(Ph))",
      "function": "Protein",
      "id": "30c5615b45480c1362e018d6252d11cf516d43941ef0cb3825ace613a49c22fc251ddb16d7bd087d9848c243f1bffc946355fca3ee0c1c4ade5d319ad644fd2a",
      "name": "MTOR",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:OGA)",
      "function": "Protein",
      "id": "70112cfa39e7f9e64515734dae8cbb9d9c5e6e59ce1a66837851a54fffd09e795a99ec1aac520290ebd1de2494896350e154af05c3760ec1cf40c68697f8a001",
      "name": "OGA",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:OGT)",
      "function": "Protein",
      "id": "42b08de710261c95b148ed72f0b3c3878d6bfc3da9088e297805e4b4a4540d1ae49e17467ff65f3a47e831a16f7628b33f54614e5f8d5709e4f2b4027e4bc366",
      "name": "OGT",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:SNCA)",
      "function": "Protein",
      "id": "4345441d1f420dc0d830377737dba9467f21b1637ed3472a697534ce698f2566b780dd52cda47c96b782242b1bcfa70e9a6147fb3bb251d1f3e1e2a0bb7038f3",
      "name": "SNCA",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:SNCA, frag(\"68_77\"))",
      "function": "Protein",
      "id": "aeacc74e639fefe3fd7d6838a4a1be58abc8e33854ec10b043888a4787f9f7f9cbb34b758eab5ed06eb8a5bbf080791872b41a942417f439912d670e6a7dfc14",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "kind": "frag",
          "start": 68,
          "stop": 77
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, frag(\"?\"))",
      "function": "Protein",
      "id": "bf9106f403a6987552600db2eb76426d8e6dd196bb7e943ee82c95c60bc16afc2f1357237011d6844ead86a4f9d0e78ec162ab52e3fc901d3baf8fb37e86ce01",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "kind": "frag",
          "missing": "?"
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, frag(\"?_*\"))",
      "function": "Protein",
      "id": "25bc8e8199c592c47a3b0ef847fe153106b18dbd146e8a19807aaaa83be3971a4b08077a417ef0b6b9958d507d59a7e336159edd8eb9a9b36e43e8ffbbb43a6f",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "kind": "frag",
          "start": "?",
          "stop": "*"
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "404fb6daed7046b1751891d9edc8f13e6cf181f228bf5dc3affeda2b6e01a99e7fde4be6fe4226551482144f1b84655db5645683bd8506c4528b3c6c08e7ca7c",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\", Ser, 87))",
      "function": "Protein",
      "id": "510569301d70538ce984319b2066a191e951c04783d2ef13f80288d562959253c1b767f2f468cd0a16231cc843073b8534dfd1f04f877d5fae52cb416af45270",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 87
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\", Ser, 87), pmod(HBP:\"O-GlcNAcylation\", Thr, 75), pmod(HBP:\"O-GlcNAcylation\", Thr, 81))",
      "function": "Protein",
      "id": "be74dddff3def47501c5a0e5a33ce7f00819d895a1560dab74d6fbe55144267556d219020b809f0512c080a752c97eef4a47c0385ba42708017bc68d587886b0",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 87
        },
        {
          "code": "Thr",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 75
        },
        {
          "code": "Thr",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 81
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\", Thr, 72))",
      "function": "Protein",
      "id": "cf8c15e9e2cf46dfd28d5b5660afc9110229aab79aa3cb1626abd38c02fa75898d3cc32fc3ba1813d33ba90db70707eec19abe43c6a57040c2ee902b90830af0",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 72
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\", Thr, 75))",
      "function": "Protein",
      "id": "517406c42b646d7cf8a8ec58ae82fda4c48e580a74c27c9cd7df947dbd450aa2415096d65fd3555c3da4236a1a50de01524a4aeff89d54d1446b21428870e638",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 75
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(HBP:\"O-GlcNAcylation\", Thr, 81))",
      "function": "Protein",
      "id": "22c7c1732e36b45880be7b038c35d16616fa502d4b7a63053e4c3a793b2ed2aa97051fbd2a9f5ebcdf323f3ee953c29a077c6dc02af40f5a9e9908132c348abc",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod",
          "pos": 81
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, pmod(Ph))",
      "function": "Protein",
      "id": "97394fdd35c1047ca232cf6a6bfaa8e991294c25a2d8e46bd3bbea9595703a8ee4c40bf39459ba6cf9eef8706e5367f4392ac005265c20eaaae0c608a9c9fbb8",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(HGNC:SNCA, var(\"?\"))",
      "function": "Protein",
      "id": "0d646c2b44d28c4acc9f9df1e5691d8250fda5b35ec7b7818be264cf143fdd8a975666a0e67d14bea4130c53464dfafa710e2c65f54a7fdc0151fc726740f440",
      "name": "SNCA",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:SOD1)",
      "function": "Protein",
      "id": "7bebe84ddc870a4ceb70828bba41ec797b861126138342942eb8124edaef94657501d4b9c4a69876b38e0fba2ff4cd5a91b560173b73723f03809ed503e90e98",
      "name": "SOD1",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNC:SOD1, var(\"?\"))",
      "function": "Protein",
      "id": "489d0def821169265e7e27a156e90cfceba86c9192b2566cc767f80dfba25e8f19d858d93667e7c8280bca5e41c8b63db9c5e590b43bc6d0b9039bcb9afbba00",
      "name": "SOD1",
      "namespace": "HGNC",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(HGNC:VAMP2)",
      "function": "Protein",
      "id": "6c818f2d1362dbe865916238b9aea3c674022e87405ca8d0885ca53bbed181fa985f4210f8e45ae315b34295961a08e888279c8dfcf1ec556278c702fbc342cf",
      "name": "VAMP2",
      "namespace": "HGNC"
    },
    {
      "bel": "p(HGNCGENEFAMILY:Calpains)",
      "function": "Protein",
      "id": "6f97880ba837b68d16ab00a1ee99ec9158dcf80bd4e3a4b320928099280c570081c6583584961ae19d42bdf033d46a1fe95bca799ce09113da082a06b5c64555",
      "name": "Calpains",
      "namespace": "HGNCGENEFAMILY"
    },
    {
      "bel": "p(MESH:Proteins)",
      "function": "Protein",
      "id": "20fec9748aca569e46ee2703620f548aece50dde1dd6518d2833a58da6a5fc28e70918b127d515943ad659b626fa533df7854b4887e2cab8d3a7af00dea602d0",
      "name": "Proteins",
      "namespace": "MESH"
    },
    {
      "bel": "p(MESH:Proteins, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "ebea203e53c77c1f06d577c839ba21f7705fdcbd5995ba399d2aaad5e9cc3daa8f0a0a0a9a4ba49842cad6de5fbeebb9b49b1752b2185328eddb4c1352ae53dc",
      "name": "Proteins",
      "namespace": "MESH",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt)",
      "function": "Protein",
      "id": "7d94454106658b1e4190b417a419f7ccbab4b525157cd679cbb4da8a006b08c3819b0a360b692358b3f80ea2648890248be2aa7c97e1d59962dc6aa097560f2d",
      "name": "Mapt",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Mapt, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "bbcb2df365693602eaf0dc8146b0e49b0c110fa73bbb3aec3b0e60e613d232072ee14723f18b985e7a5c44a10c0cec38d179fd55bd32eb13050c72c6e1fe3c01",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(HBP:hyperphosphorylation))",
      "function": "Protein",
      "id": "288a16bac682506988ebfa8afae90f04174b60844d23b90b45b4b0c9707eec496ff8c6b60c60d12b5b6519bfd5c1ea73cc7cf89166b95b0e1cb01b21e3d3ed0c",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": {
            "name": "hyperphosphorylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph))",
      "function": "Protein",
      "id": "866eb2548d3ebb8c575db22b2dbbed794da750619a04d31b30c8ffbd59b1562d89d2191f4ea30cc09874d9d44f251a203918593f4cc4e29a12eb1d52d0f58bd4",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph, Ser, 202), pmod(Ph, Ser, 205))",
      "function": "Protein",
      "id": "704361a51e309e6d7d7259217a6a36130d0697a68b0cf9ad653bd9053a58be1beee3af1b9e29529aab449a6714f3eadf6e45bb14b8917512ce5d97b13e8fdb64",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 202
        },
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 205
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph, Ser, 356))",
      "function": "Protein",
      "id": "c7c601a00fbfe9d06d3664a903edfb06331301369b9bdb641baaff8fbe15c57d91d445881bc7feee4acd9947918547ff33f77c962bc5a797d2de330ecadebadf",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 356
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph, Ser, 396))",
      "function": "Protein",
      "id": "69b41bb93945901dccbb1dcfd9330ab59edc188609471d780f4b5edf6ef9d2256e20f679d1dd3266da2c2fa35e123f4c6c797463f998a780c57daba53fc4fea1",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph, Ser, 400))",
      "function": "Protein",
      "id": "a06fd6358cf1d994fe598c9d6eee64d552d1c744f65f91283f0175ef145154046d8636ec13630c2bebd8a29897bddf707c13d7111d65417a77e57d4e396d3298",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 400
        }
      ]
    },
    {
      "bel": "p(MGI:Mapt, pmod(Ph, Ser, 626))",
      "function": "Protein",
      "id": "7644a268cee0d05132ef5dafede0d38011b4e02b72daecc980164ef437457cb873e74fbe161de3c41a95197a0dbeedd55e27a01d1ab8e6538133e06ffcd96207",
      "name": "Mapt",
      "namespace": "MGI",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 626
        }
      ]
    },
    {
      "bel": "p(MGI:Oga)",
      "function": "Protein",
      "id": "f5d64e7a620f7aa630a3766c8d2ebc2f93b5bcf46788a71049d2b781929d4389b34e4a4031cbdb49181c83fb9b8ee79a85391331c2a83599e8d1bf9ad2f92809",
      "name": "Oga",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Sod1)",
      "function": "Protein",
      "id": "0a0c9eb82637c52ee1684eb1c168066ccb246f388999f4a9d70ce6b8c4d3296eec80fda9b3bd9bcbd820baf3d49cef02f48843b7d1c5d9000600d3a984aa2df3",
      "name": "Sod1",
      "namespace": "MGI"
    },
    {
      "bel": "p(MGI:Sod1, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "6eaf16bef5a33a45815732ae36b414e16519e457a66e3550335d78497b54b7f2ad6cec44d5650fa37370e2d40e7e2b1c6b75fadb720f638665ec137c94b6c561",
      "name": "Sod1",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(MGI:Sod1, var(\"?\"))",
      "function": "Protein",
      "id": "079d3563e35db5a199d9b32baf875021c4a807e10013d0b2a9b8cb58fafafe0b3728fa0d1026c1f7ab344c98ac5d5b840bc6a8c16fa4f514bfb9e980accba2a4",
      "name": "Sod1",
      "namespace": "MGI",
      "variants": [
        {
          "identifier": "?",
          "kind": "hgvs"
        }
      ]
    },
    {
      "bel": "p(RGD:Mapt)",
      "function": "Protein",
      "id": "d7ee72cc866dbe8148a83717b5c56b67f46b715c1c11fac47257b38efabf4f3947f73dc4a227db3e8e7a2039b162b0b1b1bbb0d7605e6e651f1dba7fedfc3bd4",
      "name": "Mapt",
      "namespace": "RGD"
    },
    {
      "bel": "p(RGD:Mapt, pmod(HBP:\"O-GlcNAcylation\"))",
      "function": "Protein",
      "id": "ae1f7741fe72c31e0b619bf8eb009be6215e084fc42620b4bf819adb1fe8650ba77df314853b62c0a4eb5b08d90876a60c781721cecf1e28d6f392312c77b751",
      "name": "Mapt",
      "namespace": "RGD",
      "variants": [
        {
          "identifier": {
            "name": "O-GlcNAcylation",
            "namespace": "HBP"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(RGD:Mapt, pmod(Ph))",
      "function": "Protein",
      "id": "3b0967909beeb3e40181b42fd6d8b686507dc30354899f69d27bf9a7ea2017d23c8c8eacece7f76cec5a6edf1718c6a64dcbe256459eaf7543b8049d477f0c96",
      "name": "Mapt",
      "namespace": "RGD",
      "variants": [
        {
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod"
        }
      ]
    },
    {
      "bel": "p(RGD:Mapt, pmod(Ph, Ser, 396))",
      "function": "Protein",
      "id": "744bfea9f94f4f19a58d6c25effeb7f01a939815eda28815374fdcdabe7e3401a49ebcf69a608f91ea328bcd2356ea45069e6c42e9fd28cf5979bcdc268e34e7",
      "name": "Mapt",
      "namespace": "RGD",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 396
        }
      ]
    },
    {
      "bel": "p(RGD:Mapt, pmod(Ph, Ser, 422))",
      "function": "Protein",
      "id": "9435b4f65f5873ee53933f91c6fa871db34598e90e1bec2c1bbc74662633dd589627d3599480d67f40036bb7f99130b73c73cb0e6df19195eaa3162ba65d21ba",
      "name": "Mapt",
      "namespace": "RGD",
      "variants": [
        {
          "code": "Ser",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 422
        }
      ]
    },
    {
      "bel": "p(RGD:Mapt, pmod(Ph, Thr, 231))",
      "function": "Protein",
      "id": "3fb25b1a41e40568bdc8b0d5f7eaca362986d336d37d480f31bf2ec2b93316307929f2bf2ce8046613acbfce0f0171d2bf62c710bb6571edd28a2f9cda3ad4ae",
      "name": "Mapt",
      "namespace": "RGD",
      "variants": [
        {
          "code": "Thr",
          "identifier": {
            "name": "Ph",
            "namespace": "bel"
          },
          "kind": "pmod",
          "pos": 231
        }
      ]
    },
    {
      "bel": "p(RGD:Oga)",
      "function": "Protein",
      "id": "c3ea3c7642ccc5326dc1bc9c4bd7b36ff5077884bb4ec28961ddc73afb5caf5cfad7b0bbd94ca1de995f59dbc87091cfcd613414d29e27ab3adca2c92f52f9ad",
      "name": "Oga",
      "namespace": "RGD"
    },
    {
      "bel": "path(HP:\"Postural instability\")",
      "function": "Pathology",
      "id": "70b5c945e50c584c02ecfbe670bc07db497f895abed0158cdd8344da543183c466225a3d894cd2db475c6100df48e5eb180c82125550a36cfcf99aec5ad797fa",
      "name": "Postural instability",
      "namespace": "HP"
    },
    {
      "bel": "path(MESH:\"Alzheimer Disease\")",
      "function": "Pathology",
      "id": "00f72839b5d655cb4cb088b0eb8874bd406284d98a2afd0bdd73de0a34adb78af374b0eb26990387f41d3b41cda0e32c1b5ff5f86ed63d0fdc841bac17865541",
      "name": "Alzheimer Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Amyotrophic Lateral Sclerosis\")",
      "function": "Pathology",
      "id": "5e56d7b5172af0ae281c2f920b132d7b2263ae5eff7b0f1c9a22347914d8c169c79314aa7738c7e68cf75fac198de894bff58cb9fd4a0cb95ab434310fa07daa",
      "name": "Amyotrophic Lateral Sclerosis",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Muscle Rigidity\")",
      "function": "Pathology",
      "id": "ae0609aa1c5bd187eff52a2d7c1f1e3b94cfe46697bbc7ea034dabbd6677b0c9657c2dcf14675bede221fa6d89ce720d7c6d4d30640526e411091c405ffe2960",
      "name": "Muscle Rigidity",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:\"Parkinson Disease\")",
      "function": "Pathology",
      "id": "d7f039170f83b3fcc27595412f3b0352cd1fe95f8481a2b1144ce311ac81bb5f0087a0a7e682f498d193e00b8e8fb29908a6e0b8e23da5ef349aeeb4723b9be0",
      "name": "Parkinson Disease",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Gliosis)",
      "function": "Pathology",
      "id": "46d8ab84a7ce6995389ca278324930486e96f976926c8cc7fe6a9d293d79524be3010be1e4a9cb2975094b5fe03efce5bb8a536051d0ca1cb100da38c5f62c6f",
      "name": "Gliosis",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Hyperglycemia)",
      "function": "Pathology",
      "id": "9e02f07c8f5a2672919d0531bbe49103611be330425ae84090cf5bc4a928d01ea6531b097186e128f4bd97e008e5bdcedc6ad051267850b427a9ef31da08acc6",
      "name": "Hyperglycemia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Hypokinesia)",
      "function": "Pathology",
      "id": "13e2bc0fa35f42c3cceffbc516de27b807687fcc4c8d01feda209a081a04e5c3fc0820dc8c611d0d74eb4b3fbb271305f5e32c90f0ec3e9c4ed5ea31b5aa3b78",
      "name": "Hypokinesia",
      "namespace": "MESH"
    },
    {
      "bel": "path(MESH:Inflammation)",
      "function": "Pathology",
      "id": "3196cc4c6a20279c822cae925a9b271d0224f2c8d468e3069a3ee460662be286b61db2f144c550686a9c624e58af4ffa7570f4f2384e1cb8ee40496f8cb3fa5e",
      "name": "Inflammation",
      "namespace": "MESH"
    }
  ]
}